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ACTH: adrenocorticotrophin hormon
CGRP: calcitonin gene-related peptide
CNS: central nervous system
CRF: corticotropin releasing factor
DMN: dorsal motor nucleus of the vagus
h hour
hCGRPg_37: human calcitonin gene-related peptide 8-37 amino 
acid fragment
HPA axis: hypothalamic-pituitary-adrenal axis
i . C . : intarcisternal(ly)
IL-1: interleukin-1
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i.p. : intraperitoneal(ly)
i . v . : intravenous(ly)
Paf: platelet activating factor
PBMCs peripheral blood mononuclear cells
PG: prostaglandin
PVN: paraventricular nucleus of the hypothalamus
TNF: tumor necrosis factor
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1 .  i n t r o d u c t i o n .
The gastrointestinal motility is a well organized process 
to result in the most efficient utilization of different 
nutrients ingested. One of the first steps of this processing 
is the mixing of food with digestive excretions (saliva, gastric 
acid and enzymes) followed by the delivery of the chyme to the 
small bowel. The rate of the gastric emptying along with the 
pancreatic excretion and gall bladder contraction is well 
coordinated to provide the most efficient absorption within the 
proximal small intestine. In the past two decades a new line of 
evidence was established how neural and immune system is involved 
in the organization of the gastric motility/emptying. Recently 
many data were raised to find a role for the mediators released 
during the activation of the immune system as well. A complex 
multidirectional communication exists among the immune, endocrine 
and neural systems through hormonal, paracrine and neuronal 
signals to get in concert in the regulation of gastrointestinal 
motility in response physiological or pathophysiological stimuli.
1 . 1 .  T h e  c o n c e p t  o f  s t r e s s  a n d  i t s  i m p l i c a t i o n s  o n  d i f f e r e n t  
g a s t r o i n t e s t i n a l  f u n c t i o n s .
Tissue injury or infectious diseases activate the body's 
defense mechanisms to conserve physiologic homeostasis (Kushner, 
1982). At the site of injury or infection a local inflammation 
develops which is accompanied by systemic changes. These latter 
events are designated as the acute phase response. The first 
event has the role to remove the injurious agents (s) and to 
facilitate the local repair mechanisms. The acute phase reaction
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helps the living organism to survive the damage mobilizing the 
host's defense mechanisms. Hans Selye has described the concept 
of stress in 1936 (Selye, 1936) . His original observation was 
that the living organism reacts with a specific reaction to 
different nonspecific stimuli causing stress such as physical 
damage (e.g. cold, heat, injury), chemical compounds (toxic 
injuries) and psychologic factors. The endocrine changes (e.g. 
activation of the hypophyseal-adrenocortical axis and the adrenal 
medulla) of this reaction are accompanied by specific morphologic 
changes: adrenal hyperplasia, lymphoid and thymic involution and 
gastric mucosal lesions (Selye, 1936; Szabó et al., 1990). One 
classic component of the triad of the symptoms developing in 
response to a stressor is the gastroduodenal ulceration. 
According to this observation attention has been focused on other 
gastroenteric disorders related to stress such as altered 
gastrointestinal motility. It is well established that after a 
stressful stimulus the gastric emptying is delayed or completely 
stopped while the colonic motility is increased. These motility 
alterations result in or are associated with different clinical 
symptoms such as abdominal fullness, diarrhoea or loss of 
appetite.
1 . 2 .  C o n t r o l  o f  t h e  g a s t r o i n t e s t i n a l  m o t i l i t y  d u r i n g  s t r e s s .
The notion that the central nervous system (CNS) influences 
gastrointestinal motor functions came from the observation that 
emotions and stress influence gastrointestinal motility and 
propulsion. The first report was taken by P.J.G. Cabanis nearly 
200 years ago, negative emotions get the gastrointestinal system 
cease digestion (Cabanis, 1802) . Walter Cannon has observed that
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stress results in the alteration of gastric motor activity 
(Cannon, 1902). In spite of these early observations a long time 
must have been elapsed for the brain- gut interactions to get in 
focus of gastrointestinal research. It is evident that different 
neuropeptides act at different chemosensitive sites in the 
central nervous system or the periphery. The key mediator of 
stress induced gastrointestinal motility disturbances seems to 
be the corticotropin releasing factor (CRF).
Exogenous injection of CRF into specific brain sites and 
endogenous activation of brain CRF pathways by stress are well 
established for their role in altering gastrointestinal function 
(Taché et al. , 1993). CRF differently influences the upper or 
lower gastrointestinal tract. In particular, CRF injected into 
the cerebrospinal fluid or PVN or activation of CRF neurons in 
the PVN by various stressors inhibits gastric emptying and 
stimulates colonic motor function through an action mediated by 
the autonomic nervous system (Taché et al. , 1993) . This is 
independent of the endocrine effect of the peptide (Taché et al. ,
1993) .
Many locations of CRF also were established outside the CNS 
such as peripheral T and B lymphocytes (Stephanou et al., 1990), 
testes (Dufau et al. , 1993), trophoblastic and decidual tissue 
(Petraglia et al. , 1990), pancreas (Petrusz et al. , 1983), 
different types of cancers (Suda et al. , 1984a) and the human 
gastrointestinal tract (Kruseman et al., 1982; Kawahito et al.,
1994) , or capsaicin sensitive primary afferent neurons (Skofitsch 
et al., 1984; Kamilaris et al., 1992). CRF injected not only i.c. 
but i.v. delays gastric emptying (Taché et al., 1987; Sheldon et 
al. , 1990; Barquist et al., 1992).
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1 .3 . T h e  r o l e  o f  I n t e r l e u k i n - 1/3 i n  t h e  a c u t e  p h a s e  r e a c t i o n .
The term interleukin (IL) was first proposed in 1979 
(Dinarello, 1984a). The name interleukin-2 was given to a 
compound originated from lymphocytes which stimulated T-cell 
proliferation. That time macrophage products bearing various 
properties of interleukin-1 had been known under different names. 
Now it is widely accepted that endogenous pyrogen, lymphocyte- 
activating factor, leukocytic endogenous mediator are 
collectively referred to as interleukin-1 (Dinarello, 1984a). IL-
I exists in two forms alpha and beta which are the products of 
distinct genes sharing only 26% of amino acid homology 
(Dinarello, 1988) . However the two forms of IL-1 binds to the 
same receptor and exerts a similar biological activity the alpha 
form is less potent than the beta (Katsuura et al., 1985; Rivier 
et al., 1989b; Ishikawa et al., 1990; Saperas et al., 1990;) . IL- 
1/3 is a very potent molecule acting in the femtomol range 
(Saperas et al. , 1990; Uehara et al. , 1990). There are two 
receptors for interleukin-1: the 80 kilodalton type I receptor 
was characterized on T cells/fibroblasts, the 60 kilodalton type
II receptors are present on B cells and macrophages (Dinarello 
et al. , 1991) . The central nervous system action of IL-1 /3 is 
mediated by type I receptors (Farrar et al. , 1987) . A physiologic 
antagonist compound of IL-1 (interleukin-1 receptor antagonist: 
IL-lra) was isolated form IgG activated monocytes which is 
structurally very closely related to IL-1 (Carter et al., 1990; 
Eisenberg et al. , 1990; Hannum et al. , 1990; Arend, 19 91; 
Dinarello et al. , 1991) . IL-lra shows a lack of intrinsic 
activity (Dinarello et al., 1991), and in previous experiments 
a 1000 fold excess of IL-lra is required to block different
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actions of IL-1/3 (Hetier et al. , 1988; Dinarello et al. , 1991;
Saperas et al., 1992a; Saperas et al., 1993).
1 . 4 .  C e n t r a l  n e r v o u s  s y s t e m  a c t i o n  o f  I L - 1 / 3 .
1 .4 .1 . L o c a l i z a t i o n  o f  I L - 1 / 3  a n d  I L - 1  r e c e p t o r s  w i t h i n  t h e  
c e n t r a l  n e r v o u s  s y s t e m .
IL-1/3 was originally described as the primary product of 
immune cells (Dinarello, 1984a; Oppenheim et al., 1986; 
Dinarello, 1988), but recently a neuromodulator/neurotransmitter 
role is being emphasized for this peptide (Rothwell, 1991): (1.)
Immunoreactive IL-1/3 was found in the rat forebrain both in 
hypothalamic and extrahypothalamic sites involved in the 
regulation of hypophysiotropic, autonomic, limbic and 
extrapyramidal functions (Breder et al. , 1988 ; Lechan et al. ,
1990). (2.) IL-1 is released mostly by microglial cells and, to
a lesser extent, by astrocytes (Giulian et al. , 1986; 
Nieto-Sampdero et al., 1987; Hetier et al., 1988; Fabry et al., 
1993; Lee et al., 1993). (3.) In response to damage or convulsion 
an excess amount of IL-1/3 or IL-lmRNA is expressed 
(Nieto-Sampdero et al. , 1987; Higgins et al. , 1991; Minami et
al. , 1991) in the brain. (4.) High affinity IL-1/3 receptors are 
localized and expressed primarily in association with neurons in 
the brain (Farrar et al. , 1987; Katsuura et al. , 1988a; Lechan
et al., 1990; Takao et al., 1990; Cunningham et al., 1993).
There are several implications how circulating interleukin-1 
can reach brain to influence different functions (Hashimoto et 
al., 1991): (1.) IL-1 binds to endothelial cell IL-1 receptors
resulting in the production of further messengers such as
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arachidonate metabolites (Dejana et al. , 1987) , nitric oxide (Lin 
et al., 1996) or IL-1 itself (Warner et al., 1987). (2.) There 
is also evidence that, systemic IL-ljS can reach the brain (Banks 
et al. , 1989; Banks et al. , 1991a; Hashimoto et al. , 1991; 
Cunningham et al., 1992;) through a saturable, carrier mediated 
transport system (Banks et al. , 1991b), (3.) Large molecules such 
as IL-ljS may penetrate the blood-brain barrier at sites where it 
is fenestrated (orgánum vasculosum laminae terminális) to reach 
CNS neurons, (4.) IL-ljS may have a peripheral receptor in the 
liver to stimulate hepatic afferents (Niijima, 1992) . The central 
action of IL-ljS are long lasting since IL-1 degrades very slowly 
within the central nervous system (Banks et al., 1991a; Banks et 
al., 1991b) and the cytokine induces its own gene expression and 
production (; Walter et al., 1989; Wang et al., 1991) .
1 . 4 . 2 .  I n t e r a c t i o n  b e t w e e n  I L - 1  a n d  C R F .
There are strong evidence that IL-1 may interact with CRF 
containing neurons resulting in their activation: Peripheral or 
central injection of IL-1S activates corticotrophin releasing 
factor (CRF) neurons in the paraventricular nucleus of the 
hypothalamus (PVN) and the release and synthesis of hypothalamic 
CRF (Sapolsky et al., 1987; Bernardini et al., 1990a; Bernardini 
et al., 1990b; Saphier et al., 1990; Ju et al., 1991; Navarra et 
al. , 1991; Watanabe et al. , 1991) . There is evidence that
prostaglandins (PGs) may be part of the mechanisms mediating 
hypothalamic CRF release (Katsuura et al., 1985; Bernardini et 
el., 1990a; Bernardini et al. , 1990b; Katsuura et al. , 1990;
Navarra et al., 1991).
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1 . 4 . 3 .  E f f e c t s  o f  I L - 1 / 3  o n  d i f f e r e n t  g a s t r o i n t e s t i n a l  f u n c t i o n s .
Circulating IL-1/3 may reach the gastrointestinal system or 
neural sites which are in association with the regulation of 
different gastrointestinal functions. There are several lines of 
evidence which have shown that IL-1/3 is expressed within the 
gastrointestinal system during illness or damage: (1.) In 
patients suffering from inflammatory bowel disease a higher level 
of IL-1 was detected in intestinal biopsies (Brynskov et al. , 
1992; Reimund et al. , 1996), (2.) Rat gastric fundus stripes 
produced measurable amount of IL-1/3 (Montuschi et al. , 1996), 
(3.) IL-1/3 is the putative mediator of the changes of cholinergic 
nerve function since IL-1/3 suppressed the release of 
acetylcholine from isolated rat myenteric plexus (Main et al. ,
1993) .
IL-1/3 administered peripherally (i.v. or i.p.) or centrally 
(i.c. or i.c.v. or into specific brain nuclei) alters different 
gastric functions such as gastric acid and pepsin secretion, 
gastric emptying, intestinal and colonic motility. IL-1/3 was also 
shown to protect the gastric mucosa against various damaging 
agents (Uehara et al. , 1990; Wallace et al. , 1990; Okumura et 
al. , 1991; Robert et al., 1991a; Robert et al., 1991b; Shibasaki 
et al. , 1991; Perretti et al., 1992; Uehara et al., 1992a; 
Wallace et al., 1992).
1 . 4 . 3 . 1 .  E f f e c t s  o f  I L - 1  o n  g a s t r o i n t e s t i n a l  s e c r e t i o n .
Human recombinant IL-1/3 injected into the cerebrospinal 
fluid (i.c. or i.c.v.) impairs gastric secretion of conscious
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rats with pylorus ligation (Ishikawa et al., 1990; Saperas et 
al. , 1990; Uehara et al. , 1990) . Mainly the volume of gastric 
acid secretion was smaller, the decrease of acid concentration 
contributed to a lesser extent to the reduction of gastric acid 
output (Ishikawa et al., 1990; Saperas et al., 1990; Uehara et 
al. , 1990) . IL-ljS is more potent (Ed50= 4.5 ng) and has a longer 
lasting effect than peptides such as bombesin, calcitonin, 
calcitonin gene related peptide, CRF, opioid peptides and 
neurotensin injected centrally to inhibit gastric acid secretion. 
This phenomenon may be related to the slow degradation of IL-1 
within the central, nervous system (Banks et al. , 1991a; Banks et 
al. , 1991b) or by the induction its own gene expression and 
production (Walter et al., 1989; Wang et al., 1991). Recombinant 
human IL-1/3 injected i.p. at various doses reversed the net water 
absorption of the proximal colon into secretion (Theodoru et al. ,
1994) . This action of IL-ljS was dose dependent, involved neural 
elements and mast cell degranulation with the release of 
mediators such as prostaglandins (Theodoru et al., 1994) .
1 . 4 . 3 . 2 .  E f f e c t s  o f  I L - 1  o n  g a s t r o i n t e s t i n a l  m o t i l i t y .
Peripheral administration of IL-1S either i.p. or i.v. is 
also known to inhibit gastric emptying of a solid meal or a 
methylcellulose solution (Robert et al. , 1991a; Robert et al. , 
1991b; McCarthy et al., 1992; van Miért et al., 1992). However, 
the mechanisms through which peripheral administration of IL-lS 
suppresses gastric emptying are still not known. Since peripheral 
injection of IL-lE stimulates PVN neurons containing CRF as shown 
by c-fos expression in this nuclei (Chan et al., 1993; Brady et 
al • , 1994; Ericsson et al. , 1994) and results in CRF release
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(Berkenbosch et al., 1987; Sapolsky et al., 1987; Barbanel et 
al., 1989; Tsagarakis et al., 1989; Saphier et al., 1990; Suda 
et al., 1990; Watanabe et al., 1990; Ju et al., 1991; Watanabe 
et al., 1991). Data have shown a role for prostaglandins (PGs) 
in the release of CRF by IL-1 (Bernardini et al. , 1990a; 
Bernardini et al., 1990ba; Navarra et al., 1991). Based on these 
data, gastric stasis induced by peripheral IL-lK may involve 
central prostaglandin mediated CRF release.
IL-lS delivered into the cerebrospinal fluid (CSF) inhibits 
gastric emptying of a non nutrient semi-liquid meal while 
stimulating colonic motility through central CRF dependent 
mechanisms in rats (Fargeas et al., 1993).
1 . 5 .  T h e  r o l e  o f  b a c t e r i a l  l i p o p o l y s a c c h a r i d e  i n  t h e  r e g u l a t i o n  
o f  d i f f e r e n t  g a s t r o i n t e s t i n a l  p a t h o l o g i c a l  c o n d i t i o n s .
1 . 5 . 1 .  B a c t e r i a l  l i p o p o l y s a c c h a r i d e .
Lipopolysaccharide (LPS), the major constituent of the outer 
layer of gram negative microorganisms, is the most well known 
molecule released from infecting bacteria which stimulates the 
immune system to defend against infection. The chemistry of LPS 
was primarily elucidated by Westphal: endotoxin consists of a
core polysaccharide, the O-specific antigen and the lipid A which 
determines the biologic activity (Galanos et al., 1977; Westphal 
et al. , 1983) . LPS according to its local action to result in
inflammation at the site of infection may enter the circulation 
resulting in profound systemic effects, such as fever, acute 
phase reaction, neutropenia or in the most severe cases septic
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shock or disseminated intravascular coagulation (Cybulsky et al. , 
1988) . Injection of LPS into experimental animals mimics the 
symptoms of gram negative bacterial infections or septic shock 
as well.
1 . 5 . 2 .  E f f e c t s  o f  b a c t e r i a l  L P S  o n  t h e  h o s t s  d e f e n s e  m e c h a n i s m s .
Endotoxin injection results in the release of cytokines 
interleukin-1(8 (IL-1/3) and tumor necrosis alpha (TNFa) (Sirko et 
al., 1989; Zuckerman et al., 1989; Ulich et al., 1990; Foster et 
al., 1993). According to this widely accepted macrophage 
originated mediators of LPS action, several other compounds were 
suggested to be involved in different actions of LPS: arachidonic 
acid metabolites (Sirko et al. , 1989) , platelet-activating factor 
(Paf) (Whittle et al., 1987), nitric oxide (Nava et al., 1992), 
calcitonin gene-related peptide (CGRP) (Griffin et al. , 1992;
Wang et al. , 1992b; Hüttemeier et al. , 1993) , and opioid peptides 
(Hamilton et al., 1986; Ulich et al., 1990).
1 . 6 .  I n t e r a c t i o n  b e t w e e n  L P S  a n d  t h e  C N S .
Recent studies indicate that the action of endotoxin is 
mediated at least partly by the central nervous system (CNS). 
Endotoxin was found to activate the hypothalamic-pituitary- 
adrenal (HPA) axis (Rivier et al., 1989a; Long et al., 1990), to 
suppress plasma gonadotropin levels (Long et al., 1990; Rivier, 
1990), to induce IL-1/3 within the CNS (Koenig et al. , 1990; 
Hillhouse et al., 1993; Wan et al., 1993) and other peripheral 
sites (Ulich et al., 1990) as well. The pathway of the activation
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of the HPA axis depends on the dose of LPS administered: (1.) low 
doses utilize macrophage produced IL-1/3, (2.) high doses activate 
the HPA axis in a macrophage-independent manner, releasing IL-1, 
IL-6 or PGE2 from endothelial cells (Derijk et al. , 1991; Tilders 
et al., 1994). LPS activates the sympatoadrenal system, acting 
at dual sites: (1.) the plasma norepinephrine level is dependent 
on the CNS, (2.) whereas the plasma epinephrine response involves 
both central and peripheral regulation (Zou et al., 1993). LPS 
administration both into the central nervous system or to 
peripheral sites (i.v. or i.p.) produces c-fos in medullary and 
hypothalamic site§ which are involved in the regulation of 
different autonomic functions (Wan et al., 1993; LePard et al.,
1994) . The vagus nerve is involved in the CNS-mediated response 
to LPS since (1.) subdiaphragmatic vagotomy suppresses the CRF 
and ACTH release stimulated by a low dose of LPS (Gaykema et al. ,
1995) , (2.) hepatic vagotomy abolishes LPS or lithium chloride- 
induced hyperalgesia (Watkins et al., 1994).
1 . 7 .  T h e  r o l e  o f  c a p s a i c i n - s e n s i t i v e  p r i m a r y  s e n s o r y  a f f e r e n t s  
a n d  C G R P  i n  t h e  r e g u l a t i o n  o f  g a s t r i c  m o t i l i t y .
Capsaicin sensitive primary sensory afferents are involved 
in the postprandial regulation of the upper gastrointestinal 
tract (Holzer et al., 1994; Raybould et al., 1994; Zittel et al., 
1994) and in ileus due to surgery and/or peritoneal irritation 
(Holzer et al., 1986; Holzer et al., 1992; Plourde et al., 1993b; 
Takeuchi et al., 1996) in rats. a-CGRP an alternative splicing 
product of calcitonin gene (Rosenfeld et al. , 1983) is abundantly 
localized within the gastrointestinal tract. Mostly it is stored
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in and released from primary sensory afferent fibres arising from 
the dorsal root ganglia, a smaller amount was shown in fibres 
originating from nodose ganglia (Sternini, 1992). CGRP injected 
intravenously (i.v.) potently inhibits gastric acid secretion, 
motility and the development of mucosal lesions (Maggi et al., 
1987; Taché, 1991; Taché et al. , 1992a) . The C terminal fragment 
of human CGRP, hCGRP8_37 is a potent antagonist of CGRP on type 1 
receptors (Chiba et al. , 1989; Dennis et al. , 1990; Donoso et 
al., 1990). CGRP was shown to inhbit gastric emptying through 
type 1 receptors, since hCGRP8„37 reversed the inhibiton of gastric 
emptying induced by the i.v. injection of CGRP (Plourde et al., 
1993a) . According to the neuronal localization of CGRP a non 
neural, source was also described: it is highly likely that 
gastric mucosal lymphocytes synthesize CGRP mRNA and CGRP as well 
(Jakab et al., 1993).
1 . 7 . 1 .  I n t e r a c t i o n  b e t w e e n  c a l c i t o n i n  g e n e - r e l a t e d  p e p t i d e  a n d  
LPS.
It is well established that LPS results in a marked increase 
of plasma calcitonin gene-related peptide during endotoxic shock, 
and it seems to mediate hemodynamic changes during endotoxicosis 
(Wang et al. , 1991; Griffin et al. , 1992 ; Wang et al. , 1992a; 
Wang et al. , 1992b; Hüttemeier et al. , 1993) . Prostaglandins were 
found to trigger CGRP release during the development of 
endotoxicosis (Wang et al. , 1992a), dexamethasone was found to 
attenuate the increase of plasma CGRP content after LPS challenge 
of experimental animals (Wang et al., 1991).
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1 8. E f f e c t  o f  L P S  o n  d i f f e r e n t  g a s t r o i n t e s t i n a l  f u n c t i o n s .
LPS injection into experimental animals alters different 
gastric and intestinal functions. LPS inhibits gastric acid 
Secretion (Uehara et al., 1992b; Saperas et al., 1994; Terao et 
al. , 1995), impairs gastric mucosal blood flow and mucosal 
integrity (Whittle et al., 1987; Pique et al. , 1988;) and alters 
colonic water and electrolyte transport (Ciancio et al., 1992). 
LPS administration disrupts intestinal motility (Pons et al. , 
1989) and increases intragastric pressure in rats (Esplugues et 
al., 1989). Little is known about the mediators of the 
gastrointestinal effect of LPS. Platelet activating factor (Paf) 
and PGs are involved in intestinal motor alterations (Pons et 
al. , 1989) : Paf seems to mediate intragastric pressure (Esplugues 
et al., 1989) after LPS treatment.
1 . 9 .  A i m s  o f  t h e  e x p e r i m e n t s .
(1.) To investigate the influence of intracisternal (i.c.) or 
intravenous (i.v.) injection of IL-I/? on gastric emptying in 
conscious rats.
(2.) To assess the mechanisms whereby IL-lS exerts its inhibitory 
effect using specific receptor antagonists and inhibitor of 
prostaglandin synthesis. A special attention was focused on: 
(a.) IL-I receptors,
(b.) prostaglandins,
(c.) peripheral and central CRF.
(3.) To investigate the mechanism of action of the inhibition of 
gastric emptying by i.p. LPS, a potent stimulant of the immune 
system.
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(4 .) The role of 
(a.) IL-1/3,
(b.) peripheral and central CRF,
(c.) capsaicin sensitive primary sensory afferents and 
calcitonin gene related peptide
was studied in details in the pathogenesis of delayed gastric 
emptying following LPS injection.
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2 .  I n t e r l e u k i n - I S  A c t s  i n  t h e  B r a i n  t o  I n h i b i t  G a s t r i c  E m p t y i n g  
i n  R a t s :  M e d i a t i o n  T h r o u g h  P r o s t a g l a n d i n  a n d  C R F 1 .
2 . 1 .  B a c k g r o u n d .
Interleukin-1 (IL-1) is one of the key mediators involved 
in immunological and pathological responses to infection and 
antigenic challenges (Oppenheim et al., 1986; Dinarello, 1988) . 
In addition to its immune effects, IL-1 has been implicated as 
a neurotransmitter/neuromodulator in the central nervous system 
(CNS) (Rothwell, 1991) . IL-1 is produced in the brain by 
microglial cells and, to a lesser extent, by astrocytes (Giulian 
et al., 1986; Hetier et al., 1988; Lee et al., 1993) as well as 
microvessel endothelium (Fabry et al. , 1993) . IL-l/3-like 
immunoreactivity is also found constitutively in hypothalamic 
neurons regulating neuro-endocrine functions (Breder et al., 
1988; Lechan et al. , 1990) and high affinity IL-1/3 receptors are 
localized and expressed primarily in association with neurons in 
the brain (Farrar et al., 1987; Katsuura et al., 1988a; Takao et 
al. , 1990; Cunningham et al. , 1992; Cunningham et al. , 1993). 
There is also evidence that, systemic IL-1/3 can reach the brain 
through a saturable, carrier mediated transport system (Banks et 
al. , 1989; Reimers et al., 1991; Banks et al., 1991a) and that 
IL-1/3 induces activation of CRF-containing neurons in the PVN of 
the hypothalamus (Ericsson et al., 1994, Ericsson et al., 1997) .
IL-1S administered into the cerebrospinal fluid or specific 
hypothalamic nuclei influences endocrine, thermoregulatory, 
behavioral and immune systems (Rothwell, 1991). In addition,
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recent studies indicate that central injection of IL-ljS induces 
marked changes in gastrointestinal function inhibiting gastric 
acid secretion and erosions and postprandial intestinal motility 
while stimulating cecocolonic motor activity (Taché et al., 
1992b; Fargeas et al. , 1993) . Central or peripheral injection of 
IL-lS activates corticotropin releasing factor (CRF)- containing 
neurons in the hypothalamus and the release of CRF through 
prostaglandin E2 pathways (Berkenbosch et al. , 1987; Sapolsky et 
al., 1987; Barbanel et al., 1989; Bernardini et al., 1990a; Suda 
et al., 1990; Saphier et al., 1990; Ju et al., 1991; Navarra et 
al., 1991; Watanabe et al., 1991; Chover-Gonzalez et al., 1993) . 
Such an activation of PGE2 and CRF in the brain has been involved 
in mediating several CNS actions of IL-lS (Rothwell, 1991; Taché 
et al. , 1992b; Fargeas et al. , 1993) . Central injection of CRF 
or endogenous CRF released in the brain in response to stress is 
well established to inhibit gastric motor function through 
modulation of the autonomic nervous system (Taché et al. , 1993) . 
These observations suggest that IL-lS can act in the brain to 
inhibit gastric motor function through release of these 
transmitters.
In the present study, we investigated the influence of 
intracisternal (i.c.) injection of IL-1/3 on gastric emptying in 
conscious rats. The mechanisms whereby IL-lS exerts its 
inhibitory effect were also assessed, in particular, the 
mediation through IL-1 receptors, and the role of CRF using a 
recently developed novel specific receptor antagonists, 
[DPhe12,Nle21,38, C“MeLeu37] CRF12.41 (Hernandez et al. , 1993 ; Howard et 
al • , 1993) and indomethacin as an inhibitor of prostaglandin 
synthesis (Saperas et al. , 1991) .
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2 . 2  M a t e r i a l s  a n d  M e t h o d s .
2 . 2 . 1 .  A n i m a l s .
Male Sprague-Dawley rats (Harlan Sprague Dawley, San Diego, 
CA) weighing 250-300 g, were maintained under controlled housing 
conditions of light (6 a.m. to 6 p.m.), humidity (35%-55%), and 
temperature (22 ± 2°C) for one week. Food and water were
available ad libitum. Rats were deprived of food for 18 h before 
the experiments but had access to water up to the time where 
gastric emptying was measured. All the experiments were performed 
between 12 p.m. and 4 p.m. except in the 8 h time course study 
which started at 10 a.m. and ended at 6 p.m.
2 . 2 . 2 .  G a s t r i c  e m p t y i n g  m e a s u r e m e n t .
Measurement of gastric emptying was performed as described 
previously (Taché et al. , 1987, Sütő et al. , 1994b) . Briefly, 1.5 
ml of solution containing 1.5% methylcellulose (Sigma Chemical 
Co., St. Louis, MO) and 0.05% phenol red (Sigma Chemical Co., St. 
Louis, MO) was given intragastrically through oral intubation 
with a stainless steel tube to conscious rats. Rats were killed 
by inhalation of carbon dioxide 20 min later. In each experiment, 
a rat was killed immediately after intragastric administration 
of the test solution. Stomachs were clamped at the pylorus and 
cardia ends, removed, and rinsed in 0.9% saline. Stomachs were 
then placed in 100 ml of 0.1 N NaOH, and homogenized for 30 s. 
The suspension was allowed to settle for 6 0 min at room 
temperature, and 5 ml of the supernatant was added to 0.5 ml of
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20% trichloroacetic acid. After centrifugation (2.800 rpm, for 
20 min) 4 ml of 0.5 N NaOH was added to the supernatant. The 
absorbance of the samples was read at a wavelength of 560 nm by 
spectrophotometer (Shimadzu UV-260). The gastric emptying for 
each rat was calculated according to the following formula:
gastric emptying (%) = (1 -absorbance of test sample/ absorbance 
of baseline) x 100.
2 . 2 . 3 .  D r u g s  a n d  t r e a t m e n t s .
Injections into the jugular vein (i.v.) or into the cisterna 
magna (i.c.) were performed in rats under short (2.5 min) 
enflurane anaesthesia. Rats given i.c. injections were placed in 
a stereotaxic instrument. The volumes of i.c. and i.v. injections 
were 10 pil/rat and 0.15 ml/rat respectively.
Human recombinant IL-ljS (Upjohn, Kalamazoo, MI) was 
dissolved in Ca++/Mg++ free Dulbecco's phosphate buffered saline 
(pH 7.8) . Samples were aliquoted at a concentration of 1 pig/10 
pil and stored at -70 °C. Immediately before administration, the 
stock solution of IL-ljS was diluted in 0.9% saline for i.c. 
injection or in 0.1% serum bovine albumin and 0.9% saline for 
i.v. injection. IL-ljS was injected i.c. (0.01, 0.1, or 1 ng/rat) 
or i.v. (0.01, 0.1, 1, 3, 6, or 10 ng/rat) 30 min before the 
administration of the non-caloric solution, except in one 
experiment where the solution was given at 5, 30, 60, 180 or 480 
min after i.c. IL-ljS (0.1 ng/rat) .
Interleukin-1 receptor antagonist (IL-lra) (Upjohn, 
Synergen, Boulder, CO) was dissolved in 0.9% NaCl and was 
aliquoted at the concentration of 1 pig/10 pil. Aliquots were
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stored at -70 °C, and diluted by 0.9% NaCl before the 
experiments. IL-lra or vehicle (10 /x 1) was injected i.c. at a 
dose of 100 ng/rat in 10 /x 1 immediately before i.c. injection of 
IL-1/3 (0.1 ng/10 /xl) or vehicle (10 /xl) .
Indomethacin (Sigma Chemical Co., St. Louis, MO) was 
dissolved in 1% sodium bicarbonate, and was injected
intraperitoneally (i.p.) at 5 mg/kg in 0.5 ml volume 6 0 min 
before i.c. injection of IL-1/3 (0.1 ng/rat) or vehicle.
The recently developed CRF antagonist, [DPhe12,
Nle21,38, C“MeLeu37] CRF12.41 and rat CRF (supply by Dr. J. Rivier, the 
Salk Institute, La* Jolla, CA) were synthesized and purified as 
previously described (Hernandez et al. , 1993) . Peptides were kept 
in powder form at -20 °C and immediately before the experiment, 
CRF was dissolved in saline and the CRF antagonist in distilled 
water (pH 7.0, warmed to 37° C) . [DPhe12, Nle21’38, C“MeLeu37] CRF12_41 
(10-30 /xg/rat in 10 /x 1) or vehicle (10 /xl) was injected i.c. 
immediately before the i.c. injection in 10 /xl of CRF (600 
ng/rat), IL-1/3 (0.1 ng/rat) or vehicle.
2 . 2 . 4 .  S t a t i s t i c a l  a n a l y s i s .
Results are expressed as means + SEM. Comparisons between 
two groups were calculated by Student's t test. Multiple group 
comparisons were performed by analysis of variance followed by 
Dunnett's contrast. A P value <0.05 was considered statistically 
significant.
2 . 3 .  R e s u l t s .
Control groups injected with saline either i.c. or i.v. had 
a gastric emptying rate of 57.4% ± 2.5% and 53.7% ± 1.8%
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reSpectively as measured 20 min after the intragastric 
administration of the methylcellulose phenol red solution in 
conscious rats (Fig. 2.1.). IL-1J3 injected either i.c. (0.01-1 
ng/rat) or i.v. (0.1-10 ng/rat) 30 min before the intragastric 
solution induced a dose-related inhibition of gastric emptying 
(Fig. 2.1.) . The median effective dose (ED50) was 0.1 and 3 ng/rat 
for i.c. and i.v. administration, respectively. The i.c. IL-1S 
dose of 1 ng and the i.v. dose of 10 ng inhibited gastric 
emptying by 81.5% and 88.5% respectively (Fig. 2.1.) . Time course 
studies showed that i.c. IL-liS (0.1 ng/rat) injected either 5, 
30, 60, 180, 360 and 480 min before the intragastric 
administration of the solution induced a similar decrease of 
gastric emptying (30.3% + 4.8%, 27.3% ± 3.7%, 32.2% ± 3.9%, 29.0% 
+ 5.2%, and 28.8% ± 6.4%, respectively). However, gastric 
emptying was no longer inhibited when measured 480 min after i.c. 
injection of IL-ljS (0.1 ng/rat) (Fig. 2.2.) . In rats injected 
i.c. with vehicle, gastric emptying was not different during the 
time course study, except, when measured after 8 hours (Fig.
2.2.) . Gastric emptying was 71.4% ± 4.8% when assessed 480 
minutes after vehicle injection under short enflurane anesthesia 
compared with 47.4% + 6.9% when measured 5 minutes after vehicle 
injection (P< 0.05) .
IL-lra, injected i.c. at 100 ng/rat completely prevented 
the inhibitory effect of IL-1/3 (0.1 ng/rat, i.c.) on gastric 
emptying (Fig. 2.3.) . When given alone, IL-lra did not influence 
basal gastric emptying (Fig. 2.3.) .
I.c. injection of CRF (600 ng) and IL-1S (0.1 ng) inhibited 
gastric emptying by 69.7% and 62.3% respectively (Fig. 2.4.). The 
newly developed CRF antagonist, [DPhe12, Nle21,38, C“MeLeu37] CRF12_41 
injected i.c. at doses of 10 or 20 /xg had no effect on basal 
gastric emptying (gastric emptying: vehicle, 61.4% + 4.5%; CRF
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Pig. 2.1. Dose-related inhibition of gastric eaptying by i.c. or i.v. 
injection of IL-IE in conscious rats. Pats under short enflurane 
anesthesia were injected with vehicle or IL-1S at various doses and 30 
Bin later, the 20 Bin rate of gastric eaptying was leasured. Bach point 
represents the lean ♦ SBH of nuaber of rats indicated in parentheses. 
*- P<0.05 and ***- P<0.001 coapared respective i.c. or i.v. vehicle- 
treated group.
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Fig. 2.2. Tine course inhibition of gastric emptying induced by i.c. IL­
IK in conscious rats. IL-1K or vehicle vas given i.c. under short 
enflurane anesthesia and 5, 30, 60, 180, 360 or 480 min later, the 20 
min rate of gastric emptying rate vas measured. Each column represents 
the mean ♦ SEM of number of rats indicated in parentheses. *= p<0.05; 
“ *= P<0.001 compared vith respective vehicle-treated group; ♦= P<0.05 
compared vith 5 min vehicle group.
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Fig. 2.3. Reversal by i.c. IL-1 receptor antagonist of i.c. IL*1 - induced 
delayed gastric emptying in conscious rats. IL-lra or vehicle was 
injected i.c. before IL-IE or vehicle under short enflurane anesthesia 
and 30 ain later, gastric emptying was aeasured. Each column represents 
the aean * SBH of number of rats indicated in parentheses. ♦= P<0.05 
compared with vehicle-treated group, ♦= P<0.05 compared with respective 
control group.
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Vehic le C R F  ( 6 0 0  n g / r a t ,  i . c . )
IL — 1 /? (0.1 n g / r a t ,  i . c . )
CRF  antagoni s t  ( / i g / r a t ,  i . c . )
Fig. 2 - C  Influence of CRF antagonist injected i.c. on i.c. CRF- or IL- 
delated gastric eaptying. The CRF antagonist, [DPhe2 , 
Nle 1 .CTleLeu^ JCRFjj.^, or vehicle vas injected i.c. iaaediately 
before i.c. injection of vehicle, CRF or IL-iR (0.1 ng/rat) under short 
enflurane anesthesia. Gastric emptying vas aeasured 30 ain later. Bach 
point represents the sean + SBH of nuaber of rats indicated in 
parentheses. •= P<0.05 coapared vith CRF or IL-ig alone group, ♦= 
Pc0.05 coapared vith respective vehicle treated group.
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Vehic le X///Á CRF  ( 6 0 0  n g / r a t ,  i . c . )  
!L — 1/5 (0 .1 n g / r a t ,  i . c . )
0 5 0 5 0 5
I n d o m e t h a c i n  ( m g / k g ,  i . p . )
Fig. 2.5. Reversal by indoiethacin of i.c. IL-lg-induced delayed gastric 
eaptying. Indoiethacin or vehicle was given i.p. 60 tin before i.c. IL- 
18 or vehicle and 30 sin later gastric eaptying vas aeasured. Bach 
coluan represents the aean j SEN of nuaber of rats indicated in 
parentheses. *= P<0.05 coapared with vehicle-treated group.
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analog (10 /xg) : 61.4% ± 6.6%; 20 /xg: 61.1% ± 5.8%) . At the i.c. 
dose of 20 /xg, the CRF antagonist reversed the inhibitory effect 
of i.c. CRF by 86.8% CRF and that of i.c. IL-1J5 (Fig. 2.4.) by 
52%. A higher dose of the CRF analog (30 /xg, i.c.) given alone 
decreased gastric emptying by 27% (44.4% + 3.1%, n=6, P<0.05, 
data not shown).
Inhibition of gastric emptying induced by 0.1 ng i.c. IL-1/3 
was completely eliminated by indomethacin pretreatment (5 mg/kg, 
i.p.) whereas indomethacin had no effect on gastric stasis 
elicited by CRF (600 ng, i.c.) (Fig. 2.5.) . There was no 
significant difference between the magnitude of the inhibtory 
effect of i.c. CRF (17.4% ± 4.4%) and i.c. IL-l/S (23.9% ± 8.9%). 
Indomethacin injected alone did not influence basal gastric 
emptying (Fig. 2.5.).
2 . 4 .  D i s c u s s i o n .
IL-1/? (0.01-1 ng) injected into the cerebrospinal fluid at 
the level of the cisterna magna dose dependently delayed gastric 
emptying of a non-caloric test meal in conscious rats. The 
potency of i.c. IL-liS is shown by the long lasting inhibition of 
gastric emptying induced by femtomole doses. A time-course study 
was performed by varying the time intervals between the IL-1 
(injected i.c. at the ED50) and the oral administration of test 
meal. IL-1/3 inhibitory action was shown to have a short onset 
(within 20 min) , to persist over 6 h and to be reversible because 
8 h after the injection, gastric emptying was no longer 
inhibited. Likewise, the inhibition of gastric acid secretion 
(Uehara et al. , 1989; Saperas et al. , 1990) and gastroprotection 
against ethanol-induced lesions (Robert et al. , 1991b) induced 
by i.c. injection of IL-1 were reported to last more than 6
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hours. The slow degradation of IL-1 in the brain (Banks et al., 
1991b) and the ability of IL-1E to stimulate its own IL-1 gene 
expression in different tissues (Walter et al. , 1989; Wang et 
al . , 1991) may account for the prolonged biological activities 
of IL-lS. These findings indicate that IL-1/? injected i.c. 
potently inhibits not only gastric secretory (Okumura et al. , 
1990; Taché et al., 1992b) but also motor function in conscious 
rats.
Previous studies have shown that i.p. injection of IL-lS 
delays gastric emptying of a solid meal in conscious rats (Robert 
et al. , 1991a; McCarthy et al. , 1992) . In addition, biologically 
active IL-1 occurs in the systemic circulation following i.c. 
injection of IL-lS. These data raise the possibility that i.c. 
IL-1 can delay gastric emptying through leakage to the periphery. 
To ascertain that i.c. IL-1 acts in the brain, dose responses of 
IL-lS injected i.v. and i.c. were compared under the same 
conditions, i.v. injection of IL-lS (0.1-10 ng) dose dependently 
inhibits gastric emptying of liquid non caloric meal by 0-88.5%. 
These results and previous findings indicate that peripheral 
injection of IL-lS (i.v. or i.p.) delays gastric emptying of both 
non nutrient solution and solid caloric meals (Robert et al. , 
1991a; McCarthy et al. , 1992) . However, the ED50 dose of IL-1 
given i.c. (0.1 ng/rat) was found to be 30 fold lower than when 
given i.v. (3 ng/rat) . Moreover, the increased levels in the 
circulation after i.c. injection of IL-lS were observed at i.c. 
doses ranging from 100 to 500 ng which are 103 higher than the 
i.c. dose biologically active to inhibit gastric emptying. In 
addition it is unlikely that circulating IL-1 inhibits gastric 
emptying through a direct action on gastric smooth muscles 
because IL-l/S potentiates the myotropic activity of CaCl2 and PGE2 
on rat stomach strips (Mugridge et al. , 1991) . These data
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indicate that i.c. IL-1/3 acts in the brain to inhibit gastric 
emptying as shown for the inhibition of gastric acid secretion 
(Saperas et al., 1990; Taché et al., 1992b; Saperas et al., 
1992b). Preliminary studies indicate that IL-1S microinjected 
into the dorsal vagal complex inhibits stimulated gastric 
motility in anesthetized rats (Morrow et al. , 1995) . IL-1 
microinjected into the PVN, preoptic area and anterior 
hypothalamus was previously shown to inhibit gastric acid 
secretion in conscious rats (Saperas et al. , 1992b). These 
hypothalamic sites, namely the PVN of the hypothalamus are 
activated after i.c. or i.v. injection of IL-1 as shown by c-fos 
expression (Ericsson et al. , 1994; Ju et al. , 1991; Rivest et 
al. , 1992, Ericsson et al. , 1997). Chemical or electrical 
stimulation of the PVN of the hypothalamus inhibits gastric motor 
function (Sakagushi et al., 1985; Monnikes et al., 1992) 
suggesting hypothalamic and medullary possible sites of action 
for central IL-1 to inhibit gastric emptying.
The central action of IL-1/3 is expressed through specific 
interaction with IL-1 receptors. The recently identified natural 
IL-lra binds to surface cell receptors of IL-1 (Carter et al. , 
1990; Eisenberg et al., 1990; Hannum et al., 1990; Arend, 1991; 
Dinarello et al., 1991). When administered at 103 excess, IL-lra 
blocked the biological activities of IL-1/3 in various in vivo or 
in vitro studies (Dinarello et al., 1991; Saperas et al., 1992a; 
Saperas et al. , 1993) . Likewise, in the present study, IL-lra 
administered at doses 103-fold higher than IL-1/3, completely 
prevented i.c. IL-1/3-induced gastroparesis. IL-lra alone did not 
significantly modify gastric emptying. This shows the lack of 
intrinsic activity of IL-lra which is in agreement with various 
other evidence (Dinarello et al. , 1991) . The characterization and 
expression of IL-1 receptors showed that in the brain, IL-1
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receptors are mainly of type I (80-kilodalton protein) (Farrar 
et al• , 1987; Cunningham et al., 1992 ; Cunningham et al., 1993) 
which is preferentially recognized by IL-lra (Dinarello et al., 
1991)• These data suggest that i.c. IL-lfe may act through IL-1 
receptor type I.
IL-ljS has the ability to stimulate prostaglandin release 
in several cell types including astrocytes and to modulate the 
activity of brain neurons through prostaglandin dependent 
pathways (Hori et al., 1988; Hartung et al., 1989; Nakashima et 
al. , 1989; Shibata et al. , 1990). Central IL-1(8-induced 
alterations of thermoregulation and hormone secretion have been 
ascribed to brain prostaglandin release (Coceani et al. , 1988; 
Taché et al. , 1992b) . In our experiment, indomethacin injected 
i.p. at a dose that had no effect on basal gastric emptying, 
completely prevented the delayed gastric emptying in response to 
i.c. IL-1/3 injection. Likewise, i.p. injection of indomethacin 
reversed the centrally mediated action of IL-1 to induce 
inhibition of gastric acid secretion and ulcer formation (Uehara 
et al. , 1989; Saperas et al. , 1990; Robert et al. , 1991b; 
Shibasaki et al., 1991; Saperas et al., 1992b) and the 
suppression of postprandial pattern of intestinal motility 
(Fargeas et al. , 1993) . These findings suggest that prostaglandin 
pathways are involved in mediating i.c. IL-1/3-induced inhibition 
of gastric emptying, however the site and mechanisms through 
which prostaglandins are involved need to be further established.
Convergent evidence suggest that prostaglandin may be 
involved in the central action of IL-1 partly through modulation 
of CRF release. First, in vivo and in vitro studies indicate that 
IL-1 stimulates CRF secretion in the hypothalamus through 
prostaglandin dependent mechanisms (Uehara et al. , 1987; Katsuura 
et al., 1988b; Bernardini et al., 1990a; Navarra et al., 1991;
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Rivier et al., 1991). Second, stimulation of endogenous release 
of CRF in the brain is well established to inhibit gastric motor 
function in rats (Taché et al. , 1993). Third, the recently 
developed longer acting CRF antagonist, [DPhe12, 
Nie21,38, C“MeLeu37] CRF12.41 (Hernandez et al. , 1993 ; Howard et al. , 
1993) injected i.c. was able to reverse by 52% the inhibition of 
gastric emptying induced by i.c. IL-1. Likewise, i.c.v. IL-1/3- 
induced stimulation of colonic motor function was shown to be 
partially mediated by brain CRF pathways (Fargeas et al., 1993). 
The CRF antagonist was used at a 20 /xg i.c. dose that antagonized 
i.c. CRF-induced vdelayed gastric emptying while having no 
intrinsic activity. These data further established that the CRF 
antagonist is about twofold more potent than a-helical CRF9„41 in 
its ability to reverse exogenous and endogenous CRF-induced 
inhibition of gastric emptying, as reported in other in vivo 
systems (Hernandez et al., 1993; Howard et al., 1993). However, 
at a higher dose, (30 /xg/rat, i.c.), [DPhe12, Nle21,38, C“MeLeu37] CRF12_ 
41 showed agonist activity. These data suggest that prostaglandins 
may act by modulating CRF release, as previously established 
(Uehara et al., 1987; Katsuura et al., 1988b; Bernardini et al., 
1990a; Navarra et al., 1991; Rivier et al., 1991) rather than by 
altering CRF action. In the present study, i.c. injection of 
IL-1/3-induced gastric stasis was partially reversed by i.c. 
injection of a CRF antagonist, whereas indomethacin given at a 
dose that suppressed prostaglandin synthesis in both the brain 
and the stomach has been shown to provide a full blockade 
(Saperas et al. , 1991) . These findings suggest that prostaglandin 
way also exert a direct central action to influence gastric 
emptying independently of the one mediated by CRF release. PGE2 
injected into the CSF, PVN of the hypothalamus, or preoptic area 
suppresses gastric acid secretion in rats independently of CRF
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(Barocelli et al., 1991; Saperas et al., 1991; Saperas et al., 
1992b) and modulates intestinal migrating motor complexes in dogs 
(Staumont et al., 1990). So far all drugs shown to act centrally 
to inhibit gastric acid secretion also delay gastric emptying 
{Taché et al. , 1990a; Taché et al. , 1990b). However, whether 
central injection of PGE2 also influences gastric motor function 
is still unknown.
The possible pathophysiological relevance of these findings 
is supported by neuroanatomical and biological observations. IL-1 
immunoreactivity and receptors are localized in the brain 
(Giulian et al., 1986; Farrar et al., 1987; Breder et al., 1988; 
Hetier et al., 1988; Katsuura et al. , 1988a; Lechan et al., 1990 ; 
Lee et al., 1993; Takao et al., 1990; Cunningham et al., 1993). 
IL-1 production is increased in the brain in response to immune 
challenge or injury (Higgins et al. , 1991; Yan et al. , 1992). 
There is also evidence that, systemic IL-ljS reaches the brain 
through a saturable, carrier mediated transport system (Banks et 
al. , 1989; Reimers et al. , 1991; Banks et al. , 1991a) and 
activates CRF neurons in the PVN of the hypothalamus (Saphier et 
al. , 1990; Ju et al., 1991; Watanabe et al., 1991; Lee et al., 
1993). Because the IL-1 antagonist injected i.c. did not alter 
basal gastric emptying, these data suggest that under basal 
conditions, central IL-1 does not regulate gastric motor 
function. However, the potent inhibition of gastric emptying 
induced by i.c. injection of IL-lS may have implications for the 
alteration of gastric motor function during immunologic 
challenges associated with activation of IL-1 release.
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3 intravenous interleukin-1/3-induced inhibition of gastric 
emptying: Involvement of central corticotrophin-releasing factor 
and prostaglandin pathways in rats2.
3.1. Background.
Interleukin-1 (IL-1) is a cytokine which is synthesized 
primarily by effector cells of the immune system. IL-1 was 
originally described as a modulator of immune response during 
inflammation and injury (Dinarello, 1988). Compelling evidence 
suggests that IL-1 is not only involved in the communication of 
immune cells but affects non-immune organ systems, in particular 
the neuroendocrine system in the brain (Rothwell et al., 1994). 
Peripheral or central injection of IL-lE activates 
corticotropin-releasing factor (CRF) neurons in the PVN of the 
hypothalamus (PVN) and the release and synthesis of hypothalamic 
CRF (Sapolsky et al., 1987; Bernardini et al., 1990a; Saphier et 
al. , 1990; Ju et al. , 1991; Navarra et al. , 1991; Watanabe et 
al., 1991). There is evidence that prostaglandin may be part of 
the mechanisms mediating hypothalamic CRF release (Katsuura et 
al. , 1988b; Bernardini et al. , 1990a; Katsuura et al. , 1990; 
Navarra et al., 1991).
Exogenous injection of CRF into specific brain sites and 
endogenous activation of brain CRF pathways by stress are well 
established for their role in altering gastrointestinal function 
(Taché et al. , 1993) . In particular, CRF injected into the
The chapter was originally published in Digestion, 57:135-140, 
1996
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cerebrospinal fluid or PVN or activation of CRF neurons in the 
pVN by various stressors inhibits gastric emptying and stimulates 
colonic motor function through an action mediated by the 
autonomic nervous system (Taché et al., 1993). This is 
independent of the endocrine effect of the peptide (Taché et al. , 
1993). Likewise, recent studies showed that IL-1S delivered into 
the cerebrospinal fluid (CSF) inhibits gastric emptying of a non 
nutrient semi-liquid meal while stimulating colonic motility 
through central CRF dependent mechanisms in rats (Fargeas et al. , 
1993 ; Sütő et al. , 1994b) . Peripheral administration of IL-1S 
either intraperitóneally or intravenously is also known to 
inhibit gastric emptying of solid meal or a methylcellulose 
solution (Robert et al., 1991a; McCarthy et al., 1992; Sütő et 
al., 1994b). However, the mechanisms through which peripheral 
administration of IL-lS suppresses gastric emptying are still not 
known. Since peripheral injection of IL-1S stimulates PVN neurons 
containing CRF as shown by c-fos expression in this nuclei (Chan 
et al., 1993; Ericsson et al., 1994; Brady et al., 1994) and CRF 
release (Watanabe et al. , 1991), gastric stasis induced by 
peripheral IL-1JS may involve central prostaglandin mediated CRF 
release. In addition, we previously established that IL-lS is 
more potent when injected intracisternally (i.c.) than 
intravenously (Sütő et al., 1994b, Chapter 2.).
In the present study, the receptor specificity of 
intravenous IL-IS-induced inhibition of gastric emptying was 
investigated using the selective interleukin-1 receptor 
antagonist (IL-lra) injected intravenously and intracisternally 
(Dinarello et al., 1991; Arend, 1991). Possible involvement of 
CRF and prostaglandin pathways in the gastric response to 
peripheral injection of IL-lS was also explored.
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3.2. Materials and methods.
3.2.1- Animals.
Male Sprague-Dawley rats (Harlan Sprague Dawley, San Diego, 
CA) weighing 250-300 g, were maintained under controlled housing 
conditions of light (6.00 to 18.00 h) , humidity (35%-55%) , and 
temperature (21 ± 2°C) for one week. Food and water were 
available ad libitum. Rats were deprived of food for 18 h before 
the experiments but had access to water up to the time when 
gastric emptying was measured. All experiments were performed 
between 12.00. and 16.00 h
3.2.2. Gastric emptying measurement.
Gastric emptying was measured as described previously (Sütő 
et al. , 1994b) . Briefly, 1.5 ml of a solution containing 1.5%
methylcellulose (Sigma Chemical Co., St. Louis, MO) and 0.05% 
phenol red (Sigma Chemical Co., St. Louis, MO) was given 
intragastrically through orogastric intubation with a stainless 
steel tube to conscious rats. Rats were killed by inhalation of 
carbon dioxide 2 0 min later. In each experiment, a rat was killed 
immediately after intragastric administration of the test 
solution. Stomachs were clamped at the pylorus and cardia ends, 
removed, and rinsed in 0.9% saline. Stomachs were then placed in 
100 ml of 0.1 N NaOH, and homogenized for 30 s. The suspension 
was allowed to settle for 60 min at room temperature, and 5 ml 
of the supernatant was added to 0.5 ml of 20% trichloroacetic 
acid. After centrifugation (2.800 rpm, for 20 min) 4 ml of 0.5
N NaOH was added to the supernatant. The absorbance of the 
samples was read at a wavelength of 560 nm by spectrophotometer 
(Shimadzu UV-260). The gastric emptying for each rat was 
calculated according to the following formula:
gastric emptying (%) = (1 -absorbance of test sample/absorbance 
of baseline) x 100.
3.2.3. Drugs and treatments.
>k
Injections into the jugular vein (i.v.) or into the cisterna 
magna (i.c.) were performed in rats under short (2.5 min) 
enflurane anaesthesia. For intracisternal injections rats were 
placed in a stereotaxic instrument. The volumes of intracisternal 
and intravenous injections were 10 ^1/rat and 0.15-0.2 ml/rat, 
respectively.
Human recombinant IL-ljS (Upjohn, Kalamazoo, MI) was 
dissolved in Ca++/Mg++ free Dulbecco's phosphate buffered saline 
(Ph 7.8) . Samples were aliquoted at a concentration of 1 /xg/10 
Ml and stored at -70 °C. Immediately before administration, the 
stock solution of IL-ljS was diluted in 0 .1% serum bovine albumin 
and 0.9% saline for intravenous injection. In all experiments, 
except the time course study, IL-l/S was injected i.v. at the 
EDS0 (3 ng/rat) 30 min before the administration of phenol red 
methylcellulose solution as previously established (Sütő et al. , 
1994b).
Human recombinant interleukin-1 receptor antagonist (IL-lra) 
(Synergen, Boulder, CO) was dissolved in 0.9% NaCl and was 
aliquoted at the concentration of 1 [jLq/10 (il. Aliquots were 
stored at -70°C, and diluted by 0.9% NaCl before the experiments.
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IL-lra was injected intracisternally (100 ng/rat) or 
intravenously (3 mg/rat) immediately before vehicle or IL-1/3. The 
selection of the intracisternal and intravenous doses of IL-lra 
were based on our previous studies showing the reversal of 
intracisternal IL-1S (0.1 ng)-induced inhibition of gastric 
emptying under similar conditions (Sütő et al., 1994b) as well 
as the established 103:1 ratio of peripheral IL-lra:IL-lfi to 
inhibit the biological actions of peripheral IL-1 (Dinarello et 
al., 1991; Saperas et al., 1992a; Saperas et al., 1993) . Control 
rats were given vehicle either under the same conditions. 
Indomethacin (Sigma Chemical Co., St. Louis, MO) was dissolved 
in 1% sodium bicarbonate, and was injected intraperitoneally 
(i.p.) at 5 mg/kg in 0.5 ml volume 60 min before i.v. IL-1/3 or 
vehicle.
The recently developed CRF antagonist, [DPhe12, 
Nle21,38, C“MeLeu37] CRF12.41 (supplied by Dr. J. Rivier, the Salk 
Institute, La Jolla, CA) was synthesized and purified as 
previously described (Hernandez et al. , 1993) . The peptide was 
kept in powder form at -20 °C and dissolved in distilled water 
(Ph 7.0, warmed to 37°C) immediately before the experiment. 
[DPhe12, Nle21,38, C“MeLeu37] CRF12_41 (20 /xg/rat) or vehicle was injected 
intracisternally or intravenously followed by that of IL-l/S or 
vehicle. The choice of the dose of CRF antagonist given 
intracisternally was based on our previous reports showing the 
blockade of exogenous and endogenous CRF-induced inhibition of 
gastric emptying (Sütő et al., 1994b; Hernandez et al., 1993). 
In an additional experiment, [DPhe12, Nle21,38, C“MeLeu37] CRF12_41 (20 
Mg/rat) was injected i.v. immediately before i.v. injection of 
rat CRF (600 ng, supplied by Dr. J. Rivier, Salk Institute, CA) 
and 30 min later the phenol red methylcellulose solution was 
administered.
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3.2.4* Statistical analysis.
Results are expressed as means ± SEM. Comparisons between 
two groups were calculated by Student's t test. Multiple group 
comparisons were performed by ANOVA followed by Dunnett's 
contrast. A P value < 0.05 was considered statistically
significant.
3.3. Results.
The 2 0 min rate of gastric emptying of the phenol red 
methylcellulose solution measured 30 min after i.v. injection of 
vehicle under short enflurane anesthesia was 53.7% ± 1.9% (n=12). 
IL-lf. (3 ng/rat) injected intravenously 30 min before the 
orogastric delivery of the solution decreased gastric emptying 
to 30.3% ± 4.8% (n=12, P<0.05). IL-lra injected intravenously (3 
iug/rat) or intracisternally (100 ng/rat) immediately before that 
of IL-1S (3 ng/rat, i.v.) prevented by 100% and 62% respectively 
the inhibition of gastric emptying induced by IL-l/S (Fig. 3.1.) . 
IL-lra given alone either intravenously or intracisternally under 
otherwise similar conditions had no effect on basal gastric 
emptying (Fig. 3.1.).
Indomethacin (5 mg/kg, i.p.) did not influence the basal 
rate of gastric emptying in vehicle-pretreated group, but 
completely abolished intravenous IL-l/3-induced inhibition of 
gastric emptying (Fig. 3.2.). The recently developed CRF 
antagonist, [DPhe12, Nle21'38, C“MeLeu37] CRF12_41 (20 n g/rat) injected
intracisternally or intravenously did not significantly modify 
gastric emptying in vehicle-treated rats (Fig. 3.2.). The CRF
G. Sütő, 38/1.
0 3 0 3 0 100 0 100
I L— 1 ra (yLig, i .v . )  IL—1ra (ng, i . c . )
Fig. 3.1. Inhibition of intravenous IL-lS induced delay of gastric 
emptying by intravenous or intracisternal injection of IL-1 receptor 
antagonist in conscious rats. IL-lra or vehicle was injected 
intravenously or intracisternally immediately before intravenous IL-18 
or vehicle under short enflurane anesthesia and 30 min later, gastric 
emptying vas measured. Bach column represents the mean + SEH of number 
of rats indicated in parentheses. '= P<0.05 compared with vehicle- 
treated group, ♦= P<0.05 compared with respective IL-18-treated group.
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Fig. 3.2. Reversal by indomethacin of intravenous IL-18-induced delayed 
gastric emptying. Indoiethacin or vehicle was given intraperitoneally 
60 óin before intravenous IL-lK or vehicle and 30 min later gastric 
emptying was measured. Each column represents the mean i SEM of number 
of rats indicated in parentheses. *= P<0.05 compared with vehicle- 
treated group, ♦= P<0.05 compared with respective IL-lS-treated group.
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Fig. 3.3. Influence of CRF antagonist injected i.v. or i.c. on i.v. IL- 
16-induced delayed gastric euptying. The CRF antagonist, (DPhe1 , 
Nle21,j8,C°HeLeu3'jCRF12.41, or vehicle was injected i.v. or i.c. 
iamediately before injection of vehicle or IL-18 under short enflurane 
anesthesia. Gastric eaptying vas íeasured 30 sin later. Bach point 
represents the lean + SBH of nuaber of rats indicated in parentheses. 
*- P<0.05 compared with respective vehicle-treated group ♦= P<0.05 
compared vith respective IL-18-treated group.
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antagonist (20 /xg/rat) injected intravenously did not alter 
intravenous IL-IK-induced 50.6% inhibition of gastric emptying 
(pig. 3.3.) but completely prevented intravenous CRF (600 
ng/rat)-induced 58% inhibition of gastric emptying (vehicle + 
CRF: 23.3% ± 3.3%, n=4; CRF antagonist + CRF: 71.3% ± 1.3%, n=4; 
p<0.05) . By contrast, the CRF antagonist (20 ./xg/rat) injected 
intracisternally completely abolished the inhibitory effect of 
intravenous IL-1S (Fig. 3.3.).
3.4. Discussion.
Human recombinant IL-1S injected intravenously at 3 ng dose 
30 min before administration of the non-caloric solution inhibits 
the 20 min rate of gastric emptying by 50% in conscious rats as 
previously described (Sütő et al. , 1994b, Chapter 2.) . IL-1S and 
IL-la injected intraperitoneally were also reported to inhibit 
postprandial gastric emptying in conscious rats (Robert et al., 
1991a; McCarthy et al. , 1992) with an ED50 dose of 105 ng/rat 
(Robert et al., 1991a). These data indicate that peripheral 
administration of IL-1 consistently delays gastric emptying of 
both solid nutrient meal and non-nutrient solution.
IL-lra binds to IL-1 receptors and blocks the effects of 
exogenous IL-1S at doses 102"3 fold higher than that of IL-1S 
(Arend, 1991; Saperas et al., 1993) . IL-lra injected 
intravenously completely abolished the delay in gastric emptying 
induced by intravenous IL-liS at a 1:103 ratio. These results 
indicate that exogenous IL-lfi inhibits gastric motor function 
through specific interaction with IL-1 receptors. Similar 
blockade of i.p. IL-lS-induced postprandial gastric stasis was 
observed when IL-lra was injected i.p. at a 1:300 ratio (Robert
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et al., 1991a).
The mechanisms whereby IL-1S injected into the circulation 
inhibits gastric emptying through IL-1 receptor mediated events 
are poorly understood. Potential action directly on smooth 
muscles is unlikely since in isolated rat stomach strip 
preparation, IL-1S potentiates the myotropic activity of CaCl2 
(Mugridge et al., 1991). In addition, the relaxing effect of IL- 
lS on rat gastric fundus strips is not altered by indomethacin 
(Montuschi et al. , 1994). By contrast, in the present study, 
indomethacin completely prevented intravenous IL-IS-induced 
delayed gastric yemptying. Several biological actions of 
peripherally administered IL-1S have shown to be centrally 
mediated (Rothwell, 1991; Terao et al., 1993). The present data 
and available neuroanatomical evidence are consistent with a 
possible involvement of brain pathways in the delayed gastric 
emptying induced by circulating IL-lS.
We previously established that the ED50 of IL-1S inhibiting 
gastric emptying is 30 fold lower when the cytokine is injected 
intracisternally than intravenously (Sütő et al. , 1994b, Chapter 
2.). Second, IL-lra (100 ng) injected intracisternally reduced 
the response evoked by intravenous injection of IL-1E by 46%. 
This dose of IL-lra given intracisternally was previously shown 
to reverse completely the 60% inhibition of gastric emptying- 
induced by intracisternal injection of IL-1S (0.1 ng=ED50) . The 
partial reversal obtained under the present conditions may 
reflect incomplete accessibility of the IL-lra to brain sites of 
action reached by IL-lS given peripherally (Banks et al., 1989; 
Hashimoto et al., 1991; Banks et al., 1991a; Banks et al., 1991b; 
Reimers et al., 1991). Alternatively, the partial reversal may 
also result in the use of subeffective intravenous IL- 
1S:intracisternal IL-lra ratio (1:33). A 200-1000-fold excess of
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the IL-lra is required to obtain a complete reversal of IL-1 
actions by the IL-lra (Arend, 1991; Dinarello et al. , 1991; 
Saperas et al. , 1993; Rothwell et al. , 1994) . The appearance into 
the circulation of biologically active IL-1B when injected into 
the cisterna magna at doses superior to 100 ng (Robert et al., 
1991b) precluded testing higher doses of the IL-lra by this 
route. Since IL-lra and IL-1S share striking similar sequences 
(Dinarello et al., 1991), leakage of the IL-lra antagonist into 
the circulation may occur as observed for IL-lS (Robert et al., 
1991b) .
Our present and previous studies (Sütő et al. , 1994b, 
Chapter 2.) show a similarity between mediators (prostaglandin 
and CRF) that are involved in the gastric stasis induced by both 
central and peripheral routes of IL-lS administration. 
Indomethacin given i.p. at 5 mg/kg which inhibits brain and 
gastric PGE2 generation (Saperas et al., 1991), abolished IL-1S- 
induced inhibition of gastric emptying when injected either 
intracisternally (Sütő et al., 1994b, Chapter 2.) or 
intravenously (present study). By contrast, ibuprofen and 
indomethacin injected i.p. (10 mg/kg) were reported to prevent 
partly or to have no effect on the delay in gastric emptying of 
a solid meal induced by IL-1 injected i.p. at the maximal 
effective dose (Robert et al. , 1991a; McCarthy et al. , 1992) . 
These discrepancies may be related to differences in the 
experimental protocols (non nutrient liquid, vs. nutrient solid 
meal, ED50 vs maximal IL-lS doses) . Although IL-lS injected i.p. 
increased PGE2 formation in the gastric mucosa which is blocked 
by indomethacin (Robert et al. , 1991a), it is unlikely that 
indomethacin action results from the local inhibition of PGE2 in 
the stomach. Intravenous injection of PGE2 did not influence 
gastric emptying in rats while 16,16,dimethyl PGE2 injected
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intravenously or subcutaneously stimulated gastric emptying 
(Ruwart et al., 1984) . In addition the relaxing effect of IL-1S 
on rat gastric fundus strips is not modified by indomethacin 
(Montuschi et al., 1994).
Indomethacin injected i.p. at doses of 7-10 mg/kg prevents 
the activation of CRF-ACTH release induced by intravenous IL-1S 
(Ruwart et al., 1984; Katsuura et al., 1988b; Bernardini et al., 
1990; Kaatsuura et al., 1990) suggesting that peripheral IL-1&- 
induced PGE2 release in the brain is involved in the activation 
of hypothalamic CRF pathways. Intravenous injection of IL-1E 
increases the firing rate of CRF-containing neurons as well as 
the synthesis and release of the peptide or c-fos expression in 
the PVN (Saphier et al., 1990; Watanabe et al., 1991; 
Chover-Gonzalez et al. , 1993 ; Ericsson et al. , 1994, Ericsson et 
al. , 1997). CRF released endogenously by various stressors or 
central injection of CRF acts in the PVN and the dorsal motor 
nucleus of the vagus (DMN) to inhibit gastric motor function 
through autonomic pathways (Taché et al., 1993). We previously 
showed that intracisternal injection of CRF-induced delayed 
gastric emptying is not altered by peripheral administration of 
indomethacin (Sütő et al. , 1994b, Chapter 2.) . In the present 
study, the delay of gastric emptying induced by intravenous IL-1S 
was completely prevented by the newly developed CRF antagonist, 
[DPhe12, Nle21,38, C", MeLeu37] -CRF12_41 (Hernandez et al. , 1993) injected 
intracisternally but not peripherally. Taken together the 
previous and present data suggest that gastric stasis resulting 
from peripheral injection of IL-1S may involve a central nervous 
system mediated release of prostaglandin and CRF. The exact brain 
sites at which peripherally injected IL-lfi acts to induce an 
indomethacin- and CRF-dependent inhibition of gastric emptying 
are still to be investigated. The PVN has been shown to be a
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responsive site to exogenous and/or endogenous CRF-induced 
inhibition of gastric motor function and to IL-IS-induced 
suppression of gastric acid secretion [38-40] . In addition, 
recent studies showed that intravenous injection of IL-lS 
produces a robust and long lasting c-fos mRNA response in the 
autonomic-related parts of the parvocellular PVN neurons and in 
identified CRF producing cells in the PVN (Chan et al. , 1993 ; 
Ericsson et al. , 1994; Brady et al. , 1994, Ericsson et al. , 
1997) .
While the route whereby intravenous IL-1 comes to act in the 
brain remain unsettled (Rothwell et al., 1994), several 
mechanisms have been unravelled. There is evidence that systemic 
IL-1 can enter the CSF and brain parenchyma in intact form by a 
saturable, carrier mediated system and that the entry is blocked 
by IL-lra (Banks et al., 1989; Banks et al., 1991a; Banks et al., 
1991b; Reimers et al., 1991; Banks et al., 1993). Recent reports 
showing considerable IL-1 uptake by endothelial brain capillaries 
and high concentrations of IL-1 type I receptor mRNA in the 
endothelial cells of postcapillary venules throughout the rat 
brain (Wong et al., 1994) suggest that capillary beds, in 
addition to circumventricular organs, may be sites through which 
peripheral IL-1 gains entry into the brain (Banks et al., 1993; 
Brady et al., 1994).
IL-lra injected intravenously or intracisternally did not 
influence the rate of gastric emptying of a non-caloric solution 
in control rats (Sütő et al. , 1994b, Chapter 2, present study) . 
Likewise, intraperitoneal injection of IL-lra did not alter the 
postprandial rate of the gastric emptying in rats (Robert et al. , 
1991a). These results indicate that IL-1E is not involved in the 
regulation of gastric emptying under basal conditions as 
previously reported for brain CRF (Taché et al., 1993). However
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peripheral IL-lB production is increased during infection, 
inflammatory processes or stress (Ulich et al. , 1990; Korneva et 
al . , 1992) suggesting a possible role of elevated circulating IL- 
115 in the alterations of gastric motor function encountered 
during immune challenge (McCarthy et al. , 1992) . The 3 ng 
intravenous dose of IL-1S inhibiting gastric emptying is well 
within the range found in the circulation in response to 
endotoxin challenge (Derijk et al. , 1992) .
The present data further support the interactions between 
the immune system and neuronal regulation of gastric motor 
function which ma^ have implications in the understanding of 
gastric stasis associated with pathologies activating IL-1S 
release. It also strengthens the role of brain CRF in the gastric 
stasis resulting not only from psychological, physical or 
chemical stress (Taché et al., 1993) but also from immunological 
challenge increasing circulating IL-1.
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4 Endotoxin inhibits gastric emptying through peripheral release 
o f  corticotropin releasing factor and interleukin-1/8.
4.1. Background.
The local inflammation and systemic symptoms of infection 
induced by gram negative bacteria are caused by the 
lipopolysaccharide constituent (LPS) of the bacterial wall. The 
integrated endocrine, neural and immune response to a foreign 
antigen challenge „ is generally accepted as the acute phase 
reaction (Kushner, 1982; Cybulsky et al., 1988) . Many components 
of the symptoms associated with the acute phase response results 
from the disturbed function of the gastrointestinal tract: e.g. 
nausea, vomiting, abdominal fullness. Endotoxin injection into 
experimental animals mimics many of these symptoms, and alters 
different gastrointestinal functions including gastric acid 
secretion (Saperas et al. , 1994), gastric mucosal blood flow and 
mucosal integrity (Whittle et al. , 1987; Pique et al. , 1988),
intestinal motility (Esplugues et al. , 1989; Pons et al. , 1989), 
colonic water and electrolyte transport (Ciancio et al., 1992).
LPS is a potent stimulus of the activation of the immune 
system. LPS injection into experimental animals results in the 
release of cytokines interleukin-1/3 (IL-1/3) and tumor necrosis 
alpha (TNFa) (Sirko et al., 1989; Zuckerman et al., 1989; Ulich 
et al. , 1990) , arachidonic acid metabolites (Sirko et al. , 1989) , 
platelet-activating factor (Whittle et al., 1987), nitric oxide 
(Nava et al. , 1992), calcitonin gene-related peptide (CGRP)
(Griffin et al. , 1992; Wang et al. , 1992b; Hüttemeier et al. , 
1993), opioid peptides (Hamilton et al. , 1986; Ulich et al. , 
1990) . Recent studies indicate that the action of LPS is mediated
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at least partly by the CNS. LPS was found to activate the 
hypothalamic-pituitary-adrenal axis (Rivier et al., 1989a; Long 
et al • , 1990), to suppress plasma gonadotropin levels (Long et 
al., 1990; Rivier, 1990), to induce IL-ljS within the CNS (Koenig 
:et al. , 1990; Hillhouse et al. , 1993 ; Wan et al. , 1993) and other 
peripheral sites (Ulich et al., 1990) as well.
IL-1(8 injected intracisternally (i.c.) or intravenously 
(i.v.) was found to inhibit gastric emptying (Sütő et al. , 1994b; 
Sütő et al. , 1996, Chapter 2., present study). The mechanism 
stimulated by both central an peripheral injection of IL-1/3 
utilizes the medullary release of prostaglandin and corticotropin 
releasing factor (CRF) (Sütő et al., 1994b; Sütő et al., 1996, 
Chapters 2., 3.).
CRF injected i.c. stimulates autonomic pathways mediated 
inhibition of gastric emptying (Taché et al. , 1987) . Many 
locations of CRF also were established outside the CNS such as 
peripheral T and B lymphocytes (Stephanou et al. , 1990), testes 
(Dufau et al., 1993), trophoblastic and decidual tissue 
(Petraglia et al., 1990), pancreas (Petrusz et al., 1983) 
different types of cancers (Suda et al. , 1984a) and the human 
gastrointestinal tract (Kawahito et al. , 1994; Kruseman et al., 
1982) , or capsaicin sensitive primary afferent neurons (Skofitsch 
et al., 1984; Kamilaris et al., 1992). CRF injected not only i.c. 
but i.v. delays gastric emptying (Taché et al., 1987; Sheldon et 
al., 1990).
The aims of the present study were to evaluate the role of 
central and peripheral interleukin-1/3 and CRF in the 
gastroparesis elicited by intraperitoneal administration of 
specific receptor antagonists and prostaglandin synthesis 
inhibitor indomethacin.
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4.2. Materials and methods.
4.2.1. Animals.
Male Sprague-Dawley rats (Harlan Sprague Dawley, San Diego, 
CA) weighing 250-300 g, were maintained under controlled housing 
conditions of light (6 a.m. to 6 p.m.), humidity (35%-55%), and 
temperature (22 ± 2°C) for one week. Food and water were
available ad libitum. Rats were deprived of food for 18 h before 
the experiments but had access to water up to the time where 
gastric emptying was measured. All the experiments were performed 
between 12 p.m. and 4 p.m. except in the 8 h time course study 
which started at 10 a.m. and ended at 6 p.m.
4.2.2. Gastric emptying measurement.
Measurement of gastric emptying was performed as described 
previously (Sütő et al. , 1994b) . Briefly, 1.5 ml of solution
containing 1.5% methylcellulose (Sigma Chemical Co., St. Louis, 
MO) and 0.05% phenol red (Sigma Chemical Co., St. Louis, MO) was 
given intragastrically through oral intubation with a stainless 
steel tube to conscious rats. Rats were killed by inhalation of 
carbon dioxide 20 min later. In each experiment, a rat was killed 
immediately after intragastric administration of the test 
solution. Stomachs were clamped at the pylorus and cardia ends, 
removed, and rinsed in 0.9% saline. Stomachs were then placed in 
100 ml of 0.1 N NaOH, and homogenized for 30 s. The suspension 
was allowed to settle for 60 min at room temperature, and 5 ml
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of the supernatant was added to 0.5 ml of 20% trichloroacetic 
acid. After centrifugation (2.800 rpm, for 20 min) 4 ml of 0.5 
N NaOH was added to the supernatant. The absorbance of the 
samples was read at a wavelength of 560 nm by spectrophotometer 
(Shimadzu UV-260). The gastric emptying for each rat was 
calculated according to the following formula:
gastric emptying (%) = (1 -absorbance of test sample/ absorbance 
of baseline) x 100.
4.2.3. Drugs and treatments.
Injections into the jugular vein (i.v.) or into the cisterna 
magna (i.c.) were performed in rats under short (2.5 min) 
enflurane anesthesia. Rats given i.c. injections were placed in 
a stereotaxic instrument. The volumes of i.c., i.v. or i.p. 
injections were 10 (i 1/rat, 0.15 ml/rat or 2 ml/kg respectively.
LPS was injected at different doses (0.075, 0.75, 7.5, 15, 
75, /xg/kg) intraperitoneally. The gastric emptying was measured 
60 min later. Three other group of animals were treated by 7.5 
Mg/kg LPS and the gastric emptying was measured 30, 60 or 480 min 
later. Respective control groups were treated by i.p. saline (0.5 
ml) .
Interleukin-1 receptor antagonist (IL-lra) (Upjohn, 
Synergen, Boulder, CO) was dissolved in 0.9% NaCl and was 
aliquoted at the concentration of 1 /xg/10 fxl. Aliquots were 
stored at -70 °C, and diluted by 0.9% NaCl before the 
experiments. IL-lra or vehicle (10 [i 1) was injected i.c. or i.v. 
at a dose of 100, 500 ng/rat or 3 j i g / r a t in 10 [i 1 immediately
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before i.p. injection of LPS (7.5 /xg/kg) or vehicle (10 /x 1) .
The recently developed CRF antagonist, [DPhe12,
Nle21’38, C“MeLeu37] CRF12.41 and rat CRF (supply by Dr. J. Rivier, the 
Salk Institute, La Jolla, CA) was kept in powder form at -20 °C 
and immediately before the experiment it was dissolved in 
distilled water (pH 7.0, warmed to 37° C) . [DPhe12,
Nle21’38, C“MeLeu37] CRF12_41 (10-30 /xg/rat in 10 /xl) or vehicle (10 /xl) 
was injected i.c. or i.v. immediately before the i.p. injection 
of LPS (7.5 /xg/kg) or vehicle. Indomethacin (Sigma Chemical
Co., St. Louis, MO) was dissolved in 1% sodium bicarbonate, and 
was injected intraperitoneally (i.p.) at 5 mg/kg 60 min before 
i.p. injection of LPS (7.5 /xg/kg) or vehicle.
4.2.4. Statistical analysis.
Results are expressed as means ± SEM. Comparisons between 
two groups were calculated by Student's t test. Multiple group 
comparisons were performed by analysis of variance followed by 
Dunnett's contrast. A P value <0.05 was considered statistically 
significant.
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4.3. Results.
Control groups injected with saline i.p. had a gastric 
emptying rate 65.7% + 4.5% measured 60 min later. LPS injected 
at doses of 0.075, 0.75, 7.5, 15, 75, /xg/kg, i.p. dose 
dependently decreased gastric emptying (61.2% ± 8 .8%, 40.8% ± 
5.4%, 31.0% ± 10.0%, 12.6% + 2.5%, 6.9% + 2.9%, respectively) 
(Fig. 4.1.). The gastric emptying 30, 60, 480 min after LPS 
injection (7.5 /xg/kg, i.p.) was 51.7% ± 7.6%, 13.6% ± 2.45%, 
29.5% ± 2.7%, respectively (P<0.05) (Fig. 4.2.). The respective 
control groups had an emptying rate of 54.9% + 2.6%, 61.1% ± 2.1% 
and 72.5% ± 5.0%.
IL-lra injected both i.v. (3 /xg/rat) or i.c. (500 ng/rat) 
did not influence basal gastric emptying rate (57.8% ± 3.4% vs. 
61.0% ± 0.9% i.v., 58.4% ± 4.9% vs. 54.6% ± 3.9% i.c.) (Fig.
4.3. ) Intravenous IL-lra at a dose as low as 100 ng/rat fully 
reversed the inhibition of gastric emptying induced by LPS (7.5 
/xg/kg, i.p.) (27.5% ± 4.4% vs. 57.7% ± 15.3%, P<0.05) (Fig.
4.3. ) . The further increase of the dose of i.v. IL-lra (500 
ng/rat, 3 /xg/rat) did not influence the gastric emptying rate 
(55.2% ± 5.8% and 54.9% ± 8.2%, respectively). IL-lra injected 
i.c. at doses of 100, 300 and 500 ng/rat resulted in a dose 
dependent increase of gastric emptying, but the inhibition of 
gastroparesis was not complete (29.8% + 3.6% vs. 32.9% ± 7.3%, 
38.24% + 11.2%, 45.22% + 6.4%, respectively).
CRF antagonist injected either i.v. (20 /xg/rat) or i.c. (20 
/xg/rat) did not influence the gastric emptying of saline treated 
rats (59.9% ± 2.3% vs. 59.16% ± 2.1% i.v., 60.7% ± 5.2% vs. 69.6% 
± 3.3% i.c.) (Fig.4.4.). However the inhibition of gastric 
emptying was abolished after i.v. injection of CRF antagonist (20 
/xg/rat) (27.6% ± 2.6% vs. 54.3% ± 2.1%, P< 0.05), the i.c.
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Fig. 4.1. Dose related inhibition of gastric emptying by i.p. injection 
of LPS in coscious rats. Rats under short enflurane anesthesia were 
injected with vehicle or LPS at various doses and 60 ain later, the 20 
ain rate of gastric emptying was íeasured. Each point represents the 
aean t S8M of nuaber of rats indicated in parentheses. *- P<0.05 and 
**‘= PcO.OOl coapared with vehicle treated group.
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Pig. 4.2. Tine course inhibition of gastric emptying induced by i.p. LPS 
in conscious rats. LPS or vehicle was given i.p. and 30, 60 or 480 min 
later, the 20 >in rate of gastric emptying vas measured. Bach column 
represents the lean t SEH of number of rats indicated in parentheses. 
*= P<0.05 compared with respective vehicle-treated group.
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Fig. 4.3. Inhibition of i.p. LPS-induced delay of gastric emptying by
i.c. or i.v. injection of IL-Ira in conscious rats. IL-lra or vehicle 
was injected i.v. or i.c. immediately before i.p. LPS or vehicle under 
short enflurane anesthesia and 30 min later, the 20 min rate of gastric 
emptying vas measured. Each column represents the mean t SEN of number 
of rats indicated in parentheses. •= PcO.05 compared with vehicle- 
treated group, ♦= P<0.05 compared vith respective LPS-treated group.
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Pig. 4.4. Effect of indoaethacin on i.p. LPS-induced delay of gastric 
eaptying. Indoaethacin or vehicle was given i.p. 60 ain before i.p. LPS 
or vehicle and 30 ain later, the 20 ain rate of gastric eaptying was 
aeasured. Each coluan represents the aean ♦ SEM of nuaber of rats 
indicated in parentheses. *= P<0.05 coapared with vehicle-treated group.
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Fig. <.5. Influence of CRF antagonist injected i.c. or i.v. on i.p. LPS- 
induced delayed gastric emptying. The CRF antagonist, [DPheR 
Nle 1 ,C°XeLeu I C R P ^ j, or vehicle vas injected i.c. or i.v 
immediately before i.p. injection of vehicle or LPS under short 
enflurane anesthesia. The 20 min rate of gastric emptying vas measured 
30 min later. Each point represents the mean t SEM of number of rats 
indicated in parentheses, g  P<0.05 compared vitb respective vehicle- 
treated group , ♦= P<0.05 compared vith respective LPS treated group.
injection of CRF antagonist (20 /xg/kg) did not influence the 
gastric emptying (30.4% + 3.1% vs. 29.9% ± 7.2%) (Fig. 4.4.).
Indomethacin (5 mg/kg, i.p.) has no influence on the gastric 
emptying of rats injected with either saline (0.5ml, i.p.) (58.9%
+ 7.0% vs. 61.8% ± 4.0%) or LPS (7.5 pig/kg, i.p.) (24.9% + 4.3%
vs. 30.1% ± 4.2%) (Fig 4.5.)
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4.4. Discussion.
Infection with gram negative bacteria results in the 
activation of the host defense mechanisms. The phenomenon of 
acute phase response (Kushner, 1982) is mediated by various 
immune, endocrine and neural mechanisms. The injection of LPS, 
part of the outer layer of gram negative microbes, into 
experimental animals evokes responses similar to gram negative 
infection. LPS injected intraperitoneally dose dependently 
inhibited gastric emptying of noncaloric testmeal 1 h after its 
administration in conscious rats. The effect of LPS was long 
lasting (up to 8 h) and was not observed 3 0 min after i.p. 
injection of LPS. In response to LPS administration peripheral 
blood mononuclear cells (PBMCs) produce different cytokines that 
are the mediators of most actions of endotoxin (Cybulsky et al., 
1988; Ulich et al., 1990) . The actions of LPS are supposed to be 
secondary to the release of different cytokines (Cybulsky et al. , 
1988; Long et al., 1990; Ulich et al., 1990; Ban et al., 1992; 
Dunn, 1992; Ebisui et al., 1992; Saper et al., 1994). The delay 
of onset of LPS mediated inhibition of gastric emptying may be 
due to the synthesis/release of these second mediators.
One of the most proximal component of the immune cascade is 
IL-l existing in two forms of alpha and beta (Dinarello, 1988) .
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LPS (Rivier et al. , 1989a; Rivier, 1990) and IL-1 share many 
biological actions, including the activation of the hypothalamic 
pituitary adrenal axis, and suppression of the gonadal functions. 
LPS was shown to induce hypothalamic (Hillhouse et al. , 1993) and 
pituitary IL-1/3 (Koenig et al. , 1990). IL-1/3 injected both 
centrally (Sütő et al. , 1994b, Chapter 2.) or peripherally 
(Robert et al. , 1991b, Sütő et al. , 1996, Chapter 3.) delays 
gastric emptying through central PG and CRF utilizing pathway.
A specific natural IL-1 receptor antagonist was cloned and 
expressed which binds to surface cell receptors of IL-1 (Carter 
et al. , 1990; Hannum et al. , 1990; Eisenberg et al. , 19 90; Arend, 
1991; Dinarello et al., 1991). This peptide administered at 102- 
103-fold excess blocks different biological activities of IL-1 
mediated by type I receptors (Dinarello et al. , 1991; Saperas et 
al., 1992a; Saperas et al., 1993). IL-lra injected i.v. at a dose 
100 ng prevented the inhibition of gastric emptying by LPS. When 
the same dose was injected i.c. it did not influence the gastric 
emptying delayed by IL-1/3. When the dose was further increased 
up to 500 ng/rat, IL-lra inhibited the LPS-induced delay of 
gastric emptying. This action seems to be mediated by the 
peripheral leak of IL-lra because IL-lra and IL-1/3 share similar 
amino acid sequences (Dinarello et al. , 1991), and IL-1/3 was 
shown to leak to the periphery at i.c. doses superior to 100 ng 
(Wallace et al., 1992). These data have shown that LPS-induced 
gastroparesis is mediated by peripheral IL-1 acting on type I 
receptors. IL-1 most likely has a paracrine action since most of 
the data do not support measurable levels of IL-1 in plasma or 
blood during gram negative infection. However an endogenous 
pyrogen activity was observed after execise in human plasma 
(Cannon et al. , 1983) or the interleukin-1 activity of human 
plasma was increased after ovulation (Cannon et al., 1985),
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attempts to measure increase in the concentration of plasma IL-1 
were mostly unsuccessful (Dinarello et al., 1984b; Long et al., 
1990} during infection. In one experiment a pyrogenic but not 
subpyrogenic dose of LPS was shown to result in measurable 
interleukin levels in rat (Derijk et al. , 1991) and enhanced 
plasma levels of IL-1 were only found in patients suffering from 
critical illness due to infection by gram negative bacteria or 
in experimental animals injected by sublethal dose of LPS 
(Moldawer et al. , 1987; Zuckerman et al. , 1989) . A 4.2 kilodalton 
peptide was isolated from febrile patients, which was identified 
as a cleavage product of IL-1 functioning as circulating IL-1 
activity (Dinarello et al., 1984b).
A specific CRF receptor antagonist was used to test whether 
LPS inhibits gastric emptying through the release of CRF, because 
(1.) LPS inhibited gastric emptying through peripheral IL-1 /3 
(present study) and i.v. injection of IL-1/3 was shown to inhibit 
gastric emptying activating central PG and CRF mediated autonomic 
pathways, (2.) LPS at low doses was demonstrated to activate CRF 
containing CNS pathways through IL-1/3 to stimulate the 
hypothalamic-pituitary-adrenal axis (Elenkov et al. , 1992a; 
Tilders et al. , 1994) , (3.) Peripheral injection of endotoxin was 
shown by c-fos immunochemistry to result in the activation of 
neurons within the CNS which are involved in the regulation of 
different autonomic endocrine and behavioral responses during 
inflammation (Wan et al. , 1993 ; Elmquist et al. , 1993) . The 
injection of IL-1/3 resulted in the similar expression of c-fos 
suggesting that the neuronal activation elicited by peripheral 
LPS injection may be mediated by IL-1/3 (Rivest et al. , 1992; 
Elmquist et al., 1993; Brady et al., 1994; Ericsson et al., 1994; 
Ericsson et al. 1996). CRF antagonist injected i.c. did not alter 
the gastroparesis induced by LPS (Navarra et al. , 1991) . When
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injected i.v. prevented the i.p. LPS-induced inhibition of 
gastric emptying. There are several explanations why this 
opposite action of CRF antagonist can be observed upon the 
different routes of administration: (1.) Neurons, other than CRF 
containing ones are activated by LPS or IL-1/3. Both IL-1/3 (i.v.) 
and LPS (i.p.) were shown to activate oxytocin and vasopressin 
(Mouri et al. , 1993) immunoreactivity positive neurons within the 
CNS. Oxytocin is an inhibitory neuropeptide of gastric emptying 
within the central nervous system (Sütő et al., 1994a). (2.) In 
response to LPS, other mediators such as IL-6 or TNFa are 
produced (Cybulsky pt al. , 1988; Long et al. , 1990; Ulich et al. , 
1990; Dunn, 1992; Foster et al., 1993).
Although central CRF receptor antagonist did not have any 
effect on LPS inhibited gastric emptying peripheral CRF receptor 
antagonist prevented the gastroparesis elicited by i.p. LPS. CRF 
was originally described within the CNS, it was isolated as the 
primary activator of pituitary corticotrophs originating from the 
hypothalamus (Vale et al., 1981), but it is localized in other 
extrapituitary brain sites, and was shown to modulate other 
autonomic functions independent of HPA axis (Thiefin et al. , 
1989; La Feuvre et al., 1991) . A large pool of CRF was localized 
thereafter in other brain areas (Suda et al. , 1984b) and in other 
peripheral organs such as peripheral T and B lymphocytes 
(Stephanou et al. , 1990), testes (Dufau et al., 1993), 
trophoblastic and decidual tissue (Petraglia et al. , 1990), 
pancreas (Petrusz et al. , 1983), different types of cancers (Suda 
et al., 1984a) and the human gastrointestinal tract (Kawahito et 
al., 1994; Kruseman et al., 1982) as well. CRF is also present 
in capsaicin sensitive primary sensory afferents (Skofitsch et 
al. , 1984) . Peripheral CRF has different functions: delays 
gastric emptying (Taché et al. , 1987), inhibits gastric acid
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secretion (Taché et al. , 1987), mediates parturition (Petraglia 
et al. , 1990) , and it is an antireproductive factor in the testis 
(Audhya et al., 1989).
The most likely source of peripheral CRF may be represented 
by peripheral blood mononuclear cells: CRF mRNA was shown in this 
type of cells which are able to produce CRF-like immunoreactivity 
(Stephanou et al., 1990). Capsaicin sensitive primary afferents 
does not seem to be the source of peripheral CRF since in an 
other series of experiments capsaicin ablation of primary sensory 
neurones did not influence the delayed gastric emptying by LPS 
(Chapter 5.).
There are some conflicting results regarding the interaction 
between peripheral CRF and cytokines originating from PBMCs: (1.) 
IL-1 was shown to mediate the effect of CRF and AVP on /?- 
endorphin production by human PBMC (Kavelaars et al. , 1989) . This 
finding was not confirmed in subsequent studies (Sobel, 1990; 
Woudenberg et al. , 1992) . (2.) CRF+AVP or IL-la/)3 were shown to 
stimulate the production of ACTH-like proteins in human 
mononuclear cells, but the interrelationship between CRF and IL-1 
was not examined (Reder, 1992). (3.) A further study elucidated 
that the presence of endotoxin determines the ability of PBMCs 
to synthesize IL-1, IL-6 or TNF in response to CRF (Singh et al. , 
1990; Leu et al., 1992; Pereda et al., 1995).
Prostaglandins, depending on the species being examined, the 
type of PG and the route of administration, have various effects 
on the gastrointestinal motility (Sanders, 1984; Dubois et al., 
1987; Penston et al., 1989; Nishiyama et al., 1992; Stein et al., 
1994). LPS-induced plasma leakage and CGRP release in response 
to LPS are mediated by PGs (Wallace, 1987) , the latter phenomenon 
is inhibited by indomethacin (Wang et al. , 1992a) . Peripheral IL- 
1/3-induced inhibition of gastric emptying involves PGs (Chapter
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3.). Indomethacin did not alter the gastric emptying in LPS or 
vehicle treated rats as well. These data demonstrate that PGs do 
not mediate gastric emptying during basal conditions or after LPS 
treatment.
Based on these data the most likely mechanism of action of 
i.p. LPS to delay gastric emptying of a noncaloric testmeal is 
that LPS induces the peripheral release of CRF and IL-1 through 
a PG independent pathway. The exact site and target of these 
peptides needs further investigation, but a peripheral 
interaction at the level of PBMCs can not be excluded.
G. Sütő, 57.
5 . Non-neural calcitonin gene related peptide contributes to the 
inhibition of gastric emptying by intraperitoneal endotoxin in 
rats.
5.1. Background.
The delivery of ingested food from the stomach to the 
intestine is a well coordinated process resulting in the most 
effective utilization of different nutrients. Infectious diseases 
which activate a complex host response consisting of neural, 
immune and hormonal reactions - this latter called acute phase 
reaction (Kushner, 1982; Cybulsky et al. , 1988)- disturb the 
upper gastrointestinal motility. Lipopolysaccharide (LPS) -the 
outer layer of gram negative bacteria- injected into experimental 
animals elicits similar neural, hormonal and immune reactions to 
those observed during the development of acute phase reaction. 
This phenomenon is accompanied by altered gastrointestinal 
motility (; Esplugues et al., 1989; Pons et al., 1989; Cullen et 
al., 1995; Wirthlin et al. , 1996).
The action of lipopolysaccharide is mediated by different 
central and peripheral transmitters. It is well established that 
LPS results in a huge increase of plasma calcitonin gene-related 
peptide during endotoxic shock (Wang et al. , 1991; Griffin et 
al. , 1992; Wang et al., 1992a; Wang et al., 1992b; Hüttemeier et 
al. , 1993) . Capsaicin sensitive primary sensory afferents are 
involved in the of postprandial regulation of the motility of the 
upper gastrointestinal tract (Holzer et al., 1994; Raybould et 
al. , 1994; Zittel et al. , 1994) and in ileus due to surgery 
and/or peritoneal irritation (Holzer et al. , 1986; Holzer et al. ,
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1992; Plourde et al. , 1993b; Takeuchi et al. , 1996) in rats, ot- 
CGRP an alternative splicing product of calcitonin gene 
(Rosenfeld et al., 1983) is abundantly localized within the
gastrointestinal tract. Mostly it is stored in and released from 
primary sensory afferent fibres arising from the dorsal root 
ganglia, a smaller amount was shown in fibres originating from 
nodose ganglia (Sternini, 1992). CGRP injected intravenously 
potently inhibits gastric acid secretion, motility and the 
development of mucosal lesions (Maggi et al. , 1987; Taché, 1991; 
Taché et al. , 1992a) . The C terminal fragment of human CGRP,
hCGRP8_37 is a potent* antagonist of CGRP on type 1 receptors (Chiba 
et al., 1989; Dennis et al., 1990; Donoso et al., 1990). CGRP was 
shown to inhibit gastric emptying through type 1 receptors, since 
hCGRP8.37 reversed the inhibition of gastric emptying induced by 
the i.v. injection of CGRP (Plourde et al., 1993a). According to 
the neuronal localization of CGRP a non neural, source was also 
described: it is highly likely that gastric mucosal lymphocytes 
synthesize CGRP mRNA and CGRP as well (Jakab et al., 1993) .
The aim of the present study was to establish a role for 
endogenous CGRP in the inhibition of gastric emptying induced by 
i.p. LPS injection.
5.2. Materials and methods.
5.2.1. Animals.
Male Sprague-Dawley rats (Harlan Sprague Dawley, San Diego, 
CA) weighing 250-300 g, were maintained under controlled housing 
conditions of light (6 a.m. to 6 p.m.), humidity (35%-55%), and
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temperature (22 ± 2°C) for one week. Food and water were
available ad libitum. Rats were deprived of food for 18 h before 
the experiments but had access to water up to the time when 
gastric emptying was measured. All the experiments were performed 
between 12 p.m. and 4 p.m.
5.2.2. Measurement of gastric emptying.
Measurement of gastric emptying was performed as described 
previously (Sütő efe al., 1994b). Briefly, 1.5 ml of a solution
containing 1.5% methylcellulose (Sigma Chemical Co., St. Louis, 
MO) and 0.05% phenol red (Sigma Chemical Co., St. Louis, MO) was 
given intragastrically through oral intubation with a stainless 
steel tube to conscious rats. Rats were killed by inhalation of 
carbon dioxide 20 min later. In each experiment, a rat was killed 
immediately after intragastric administration of the test 
solution. Stomachs were clamped at the pylorus and cardia ends, 
removed, and rinsed in 0.9% saline. Stomachs were then placed in 
100 ml of 0.1 N NaOH, and homogenized for 30 s. The suspension 
was allowed to settle for 60 min at room temperature, and 5 ml 
of the supernatant was added to 0.5 ml of 20% trichloroacetic 
acid. After centrifugation (2.800 rpm, for 20 min) 4 ml of 0.5 
N NaOH was added to the supernatant. The absorbance of the 
samples was read at a wavelength of 560 nm by spectrophotometer 
(Shimadzu UV-260). The gastric emptying for each rat was 
calculated according to the following formula:
gastric emptying (%) = (1 -absorbance of test sample/ absorbance 
of baseline) x 100.
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5.2.3* Drugs and treatments.
Injections into the jugular vein (i.v.) were performed in 
rats under short (2.5 min) enflurane anaesthesia. The volumes of 
i.v. or intraperitoneal (i.p.) injections were 0.15 ml/rat or 
2 ml/kg, respectively.
LPS was injected i.p. at various doses (7.5, 15 or 75 
fj.g/kg) . Rats were given either the CGRP antagonist hCGRP8_37 (30 
H g/kg, iv.) or vehicle immediately before endotoxin.
Rats were pretreated with capsaicin (25-50-50 mg/kg, s.c. 
over 36 h) or vehicle. The ablation of capsaicin sensitive 
primary sensory afferents was confirmed by the lack of eye wiping 
in response to corneal application of 1% NH4C1. 10-14 days later 
rats were injected with hCGRP8.37 ( 30 ^.g/kg, i.v.) and LPS (7.5 
Mg/kg, i.p.) or with the respective vehicles.
5.3. Results.
The gastric emptying in vehicle-treated rats was 58.3 ± 
2.5%. LPS dose dependently decreased gastric emptying. hCGRP8_37 
partially reversed the inhibition of gastric emptying delayed by 
LPS at 7.5 jug/kg (25.5% ± 3.1% vs. 43.1% ± 2.3%, P<0.05), but not 
at doses of 15 and 75 Mg/kg (10.2% ± 1.0% vs. 14.2% ± 2.6%, 8.8% 
± 21.8% vs. 11.5% ± 2.2%) (Fig. 5.1.).
Capsaicin ablation of primary sensory afferents did not 
influence basal gastric emptying (57.4% ± 2.8% vs. 59.7% + 3.9%) 
or LPS-delayed gastric emptying (25.5% ± 3.1% vs. 30.1 ± 3.1%). 
In capsaicinized rats (devoid of corneal chemosensory response), 
hCGRP8_37 still partially reversed gastric emptying inhibited by
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Fig. 5.1. Inhibition of i.p. LPS * induced delay of gastric eiptying by
i.v. injection of hCGRPg.37 in conscious rats. hCGRPo.37 or vehicle was 
injected i.v. iaaediately before i.p. LPS or vehicle under short 
enflurane anesthesia and 30 lin later, the 20 sin rate of gastric 
eaptying vas aeasured. Bach coluan represents the aean t SBM of nuaber 
of rats indicated in parentheses. ‘= P<0.05 compared with respective 
vehicle-treated group.
G. Sütő, 60/2.
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Pig 5.2. Inhibition of i.p. LPS-induced delay of gastric eaiptying by
i.v. injection of bCGRPg.™ in conscious rats pretreated with capsaicin 
125- 50- 50 ag/kg) 2 weeks before the expedient. hCGRPg,, or vehicle was 
injected i.v. immediately before i.p. LPS or vehicle under short 
enflurane anesthesia and 30 ain later, the 20 ain rate of gastric 
emptying was aeasured. Bach coluan represents the mean t SEH of number 
of rats indicated in parentheses. *= P<0.05 compared with respective 
vehicle-treated group, ♦= compred with respective capsaicin and LPS treated group.
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LPS (30.1% ± 3.1% vs. 42.9% ± 2.8%, P<0.05) (Fig. 5.2.) . hCGRP8_37 
did not influence gastric emptying of vehicle or capsaicin 
pretreated vehicle injected rats (56.5% + 2.9% vs. 58.4 ± 2.1%).
5.4. Discussion.
LPS, a potent inducer of acute phase reaction in 
experimental animals dose dependently inhibits gastric emptying 
(Chapter 4.) . Although the CGRP receptor antagonist, hCGRP8_37 did 
not influence the action of the submaximal dose of CGRP, the ED50 
dose of CGRP was partially inhibited by the antagonist. In a 
previous study the similar dose of hCGRP8.37 was established to 
fully reverse the inhibition of gastric emptying elicited by the 
submaximal dose of CGRP (Plourde et al. , 1993a) . This may 
implicate that the dose administered can not be supposed to be 
small to inhibit CGRP on gastric emptying.
LPS results in the release of an abundant amount of CGRP 
during endotoxaemia (Wang et al. , 1991; Wang et al. , 1992a; Wang 
et al., 1992b; Wang et al., 1995) . Recent evidence has shown that 
LPS elevated plasma CGRP within 30 min after its i.v. injection 
and enhanced CGRP mRNA level of dorsal root ganglion cells 2.5 
h later (Tang et al. , 1997) . CGRP injected i.v. potently inhibits 
gastric emptying (Lenz, 1988; Plourde et al. , 1993a) . In the 
present study hCGRP8_37 a potent CGRPi receptor antagonist (Chiba 
et al., 1989; Dennis et al., 1990; Donoso et al., 1990) partially 
antagonized the inhibition of gastric emptying induced by a dose 
of LPS which results in approximately 50% inhibition of gastric 
emptying. The gastroparesis following the i.p. injection of a 
maximum effective dose of LPS was unaltered by hCGRP8_37.
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aCGRP is a product of alternative processing of calcitonin 
gene (Rosenfeld et al. , 1983) and is located primarily in the 
capsaicin sensitive primary afferents (Sternini, 1992). Capsaicin 
ablation of these neurons, confirmed by eye wiping test unaltered 
the gastric emptying of the nonnutrient testmeal. This finding 
is in line with the previous findings (Coimbra et al. , 1996) . 
Although in the present study capsaicin ablation of the capsaicin 
sensitive primary sensory afferents did not alter the 
gastroparesis induced by LPS, hCGRP8_37 was able to partially 
reduce the inhibition of gastric emptying by LPS. This latter 
finding suggests tljat in response to LPS a capsaicin resistant, 
may be a non neural source of CGRP is mobilized to inhibit 
gastric emptying of nonnutient testmeal. The non neural origin 
of CGRP is obscure. CGRP mRNA and CGRP itself was localized 
within cells settled in the gastric mucosa highly likely being 
identified as lymphocytes (Jakab et al., 1993). However a huge 
increase of serum CGRP was found in endotoxemia (Chiba et al., 
1989; Dennis et al. , 1990; Donoso et al. , 1990) immune cells were 
not proven yet to be able to produce CGRP in a sufficient amount 
to inhibit gastric emptying. Since the inhibition of gastric 
emptying was observed 1 h after the injection of the present dose 
of LPS, an inducible mediator should be suggested to result in 
the release of CGRP. The most likely mediator of LPS is IL-1 to 
release CGRP, since LPS act through IL-1 and TNF (Cybulsky et 
al., 1988; Long et al., 1990; Ulich et al. , 1990; Dunn, 1992) and 
IL-1 was shown to act partially through CGRP (Coimbra et al. , 
1996) . This hypothesis is strengthened by the ability of IL-1 
receptor antagonist injected i.p. to fully inhibit the 
gastroparesis induced by the same dose of LPS (Sütő et al. , 1996, 
Chapter 3.) . IL-ljS was shown to sensitize capsaicin sensitive
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primary afferents through local release of prostaglandins 
(Herbert et al. , 1994a) and nitic oxide (Herbert et al. , 1994b), 
but alone was unable to release any mediator form these nerve 
endings.
Taken together these data, LPS injected i.p. results in the 
inhibition of gastric emptying which is partially mediated 
through the release of CGRP. The origin of CGRP is located 
outside the nervous system since capsaicin ablation of the 
primary sensory afferents did not modify the action of LPS.
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g. Summary and conclusions.
Activation of the body's defense mechanisms during illness 
or injury involves non specific mechanisms which serve to remove 
the damaging agents and to facilitate tissue repair (Kushner, 
1982; Cybulsky et al., 1988). This process is guided by a well 
orchestrated coordination of the endocrine, immune and neural 
systems, which results in the survival of the human body. This 
phenomenon was originally described by Hans Selye more than 60 
years ago and was summarized as the concept of stress (Selye, 
1936; Szabó et al. , 1990). The involvement of the 
gastrointestinal system was very early discovered observing the 
development of gastric ulcer/erosions during stress. Stress not 
only results in gastric mucosa damage, but alters other 
gastrointestinal functions such as secretion or motility. All 
of these pathologies produce various gastrointestinal symptoms 
(e.g. loss of appetite, abdominal fullness, nausea, vomiting) for 
patients.
The thesis was focused on the mechanisms underlying the 
inhibition of gastric emptying by the most proximal inflammatory 
mediator the immune cascade (Dinarello, 1984a; Dinarello et al., 
1986 ; Dinarello, 1988) IL-ljS and LPS (Galanos et al. , 1977; 
Westphal et al. , 1983) , which is a potent stimulant of the immune 
system (Cybulsky et al., 1988).
6.1. Interleukin-16 Acts in the Brain to Inhibit Gastric Emptying 
in Rats: Mediation Through Prostaglandin and CRF.
A multidirectional communication has been supposed among the 
immune, neural and endocrine system to mediate stress response.
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It has been clarified that peptides, have not only their classic 
function (e.g. CRF to stimulate ACTH release from the anterior 
pituitary or IL-1/3 to be the primary secretory compound of 
monocytes) but are involved in the regulation of other biological 
functions (e.g. CRF is a neurotransmitter in the DMN to inhibit 
gastric emptying (Taché et al. , 1987) or IL-1/3 is localized and 
expressed within the CNS (Giulian et al., 1986; ; Lechan et al., 
1990; Higgins et al., 1991; Ban et al., 1992).
The gastric emptying was measured by a non caloric testmeal 
(1.5% methylcellulose containing 0.05% phenol red) during a 20 
min period in rats weighing 250-300g. All of the control 
(untreated or vehicle treated) rats provided an emptying rate of 
approximately 56% of the original volume of the test solution 
(1.5 ml) during this time period. It was found that IL-1/3 had an 
ED50 dose to inhibit gastric emptying 0.1 ng/rat following i.c. 
and 3.0 ng/rat following i.v. injection. The ED50 dose for central 
IL-1/3 is 3 0 fold lower than the dose for i.v. route. This 
suggests a central site of action which is supported by the 
finding which showed that there are high affinity receptors 
localized and expressed with neurons in the brain (Farrar et al. , 
1987; Katsuura et al., 1988a; Lechan et al., 1990; Takao et al., 
1990; Cunningham et al., 1993). There are several explanations 
how circulating IL-1 may reach the CNS neurons: (1.) endothelial 
cells expressing receptors for IL-1/3 (Wong et al. , 1994) may 
synthesize messenger molecules (Hashimoto et al., 1991): 
arachidonate metabolites (Dejana et al. , 1987) , nitric oxide (Lin 
et al., 1996) or IL-1 itself (Warner et al., 1987), (2.) systemic 
IL-l/3 may cross the brain-blood barrier through a saturable, 
carrier mediated transport system (Banks et al., 1989; Banks et 
al., 1991a; Banks et al., 1991b; Reimers et al., 1991; Banks et 
al. , 1993), (3.) IL-1/3 may penetrate the blood-brain barrier at 
sites where it is fenestrated for large molecules to reach CNS
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neurons: at orgánum vasculosum laminae terminális (Lin et al., 
1996), (4.) IL-1/3 may have a peripheral receptor in the liver to 
stimulate hepatic afferents (Niijima, 1992).
The central action of IL-1/3 was long lasting, at least for 
6 hours. It can be explained by the slow degradation of IL-1/3 
within the central nervous system (Banks et al. , 1991a; Banks et 
al., 1991b) and by its ability to induce its own gene expression 
and peptide production (Walter et al. , 1989; Wang et al., 1991) . 
Peripheral injection of IL-1/3 had a shorter duration of action, 
1 h after its injection the inhibition of gastric emptying is 
hardly observed (unpublished observations). This short duration 
of action correlates well with the elimination of IL-1/3 from the 
plasma mostly by the kidneys (Klapproth et al., 1989) .
The inhibition of gastric emptying by either i.v. or i.c. 
IL-1/3 was fully antagonized by IL-lra (Carter et al. , 1990; 
Eisenberg et al. , 1990; Hannum et al. , 1990; Arend, 1991; 
Dinarello et al., 1991) injected through the respective route. 
A partial inhibition (46%) of the delay of gastric emptying 
induced by i.v. IL-1/3 was observed after i.c. injection of IL- 
lra. There are several explanations why IL-lra injected i.c. 
could not fully reverse the action of i.v. IL-1/3: (1.) IL-lra may 
incompletely penetrate to brain sides which may be reached by 
i.v. IL-1/3. This explanation can be supported by the finding 
which has shown that IL-1/3 injected i.c. results in a different 
pattern of brain c-fos expression than injected i.v.. (2.) There 
is a subeffective IL-1/3: IL-lra ratio (1:33), because at least 102 
excess of IL-lra is required to inhibit the biological effects 
of IL-1/3 (Dinarello et al. , 1991; Rothwell et al. , 1994) . Higher 
doses of IL-lra were not tested because IL-lra may leak to the 
periphery in an excess of dose 100 ng. IL-1/3 injected i.c. at 
doses higher than 100 ng (Robert et al. , 1991b) were shown to 
have peripheral action. IL-lra and IL-/3 share similar sequences
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(Dinarello et al. , 1991) which may predispose IL-lra to reach the 
circulation after i.c. injection (Robert et al., 1991b). IL-ra
injected i.v. or i.c. before the vehicle of IL-1/3 did not 
influence basal gastric emptying.
A potential peripheral action directly on smooth muscles is 
unlikely, because IL-1/3 potentiated the myotropic activity of 
CaCl2 in an isolated rat stomach strip preparation (Mugridge et 
al. , 1991), and the relaxing effect of IL-1/3 on gastric fundus 
strips is not altered by indomethacin (Montuschi et al., 1994) .
These data demonstrate that IL-1/3 is not involved in the
regulation of gastric emptying in basal conditions, and further
*
confirms that IL-1/3 exerts its action on gastric emptying through 
the activation of type I IL-1 receptors (Farrar et al. , 1987;
Cunningham et al., 1992; Cunningham et al., 1993).
CRF (Vale et al. , 1981) was originally described as the
stress peptide because it stimulates the release of ACTH which 
in turn stimulates the adrenal cortex to secrete cortisol and 
corticosterone. CRF is localized in peripheral tissues such as 
T and B lymphocytes (Stephanou et al., 1990), testes (Dufau et 
al. , 1993), trophoblastic and decidual tissue (Petraglia et al. , 
1990), pancreas (Petrusz et al., 1983), different types of
cancers (Suda et al. , 1984a), the human gastrointestinal tract
(Kawahito et al., 1994; Kruseman et al., 1982) and in capsaicin 
sensitive primary sensory afferents (Skofitsch et al., 1984) as 
well. CRF is the peptide which is well established to modulate 
gastrointestinal motility during stress. Exogenous CRF injected 
into the CNS or the activation of endogenous CRF containing 
neurons inhibits the gastric emptying of a noncaloric testmeal 
and stimulates colonic motility (Buéno et al. , 1988; Lenz et al. , 
1988b; Jiménez et al., 1990; Sheldon et al., 1990; Taché et al., 
1993; Gue et al., 1994). Brain CRF utilizes autonomic pathways
to delay gastric emptying (Taché et al. , 1993) . However CRF
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injected i.v. was demonstrated to retard gastric emptying of 
noncaloric testmeal, the mechanism of action of peripheral CRF 
is still obscure (Taché et al. , 1987; Sheldon et al. , 1990; 
Barquist et al. , 1992). IL-l/S injected both i.v. or i.c./i.c.v.
stimulates CRF containing CNS neurons mostly localized within the 
PVN of the hypothalamus (Sapolsky et al. , 1987; Bernardini et
al., 1990a; Bernardini et al., 1990b; Saphier et al., 1990; Ju
et al., 1991; Navarra et al., 1991; Watanabe et al., 1991) . There 
are several line of evidence that the release of CRF from CRF 
containing neurons after IL-l/S stimulation is mediated by 
prostaglandins (Katsuura et al. , 1985; Bernardini et al. , 1990a; 
Bernardini et al., 1990b; Katsuura et al., 1990, Navarra et al., 
1991;) . The recently developed, potent CRF antagonist ( [DPhe12, 
Nle21,38, C“MeLeu37] CRF12_41) injected i.c. but not i.v. fully
antagonized the gastroparesis induced by i.v. IL-1/3 and was 
partially effective (52%) before i.c. injection of IL-1/3. 
Likewise, i.c.v. IL-l/3-induced stimulation of colonic motor 
function was shown to be partially mediated by brain CRF pathways 
(Fargeas et al. , 1993). A similar inhibition (50%) of gastric
emptying which was produced by i.c. IL-l/S was achieved by i.c. 
CRF (600 ng/rat) , and this inhibition of gastric emptying was 
prevented by i.c. CRF antagonist (20 /ig/rat) . This result leads 
to the conclusion that the dose of CRF antagonist was not 
ineffective to antagonize IL-l/S mediated 50% inhibition of 
gastric emptying. The CRF antagonist might have been unable to 
penetrate to sites where CRF was released after IL-l/S challenge 
or some other mechanisms are involved in the gastroparesis 
induced by ic. IL-l/S. This hypothesis is supported by the fact 
that indomethacin was able to fully reverse the inhibition of 
gastric emptying induced by either i.c. or i.v. injection of IL- 
1/3.
There are many conflicting data -due to differences of
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species examined, type of PG or its analog, route of
administration- regarding the role of PGs in the regulation of
gastric emptying. In general, PGs retard the emptying of solid
foods and mostly stimulate the emptying of liquids from the
stomach (Sanders, 1984; Dubois et al. , 1987; Penston et al. ,
1989; Nishiyama et al. , 1992; Stein et al. , 1994) . IL-1/3 has the
ability to release prostaglandin from several cell types
including astrocytes and modulate the activity of brain neurons
through prostaglandin dependent pathways (Fontana et al., 1982;
Hartung et al. , 1989; Nakashima et al. , 1989) . Central IL-1/3-
induced alterations of thermoregulation and hormone secretion*
have been ascribed to brain prostaglandin release (Bernardini et 
al. , 1990a; Bernardini et al. , 1990b; Watanabe et al. , 1990;
Navarra et al. , 1991; Luheshi et al., 1993) . Indomethacin 
injected i.p. reversed the centrally mediated action of IL-1 to 
inhibit gastric acid secretion and ulcer formation (Nakashima et 
al., 1989; Uehara et al., 1989; Robert et al., 1991b; Saperas et 
al. , 1992b) and the suppression of postprandial pattern of
intestinal motility (Fargeas et al., 1993). However, the sites 
and mechanisms through which PGs mediate i.c. IL-1/3-induced 
inhibition of gastric emptying is obscure. IL-1 j3 injected i.v. 
stimulates gastric mucosa prostaglandin formation (Robert et al. , 
1991a), and PGs stimulate gastric emptying (Sanders, 1984; Dubois 
et al., 1987; Penston et al. , 1989; Nishiyama et al., 1992; Stein 
et al., 1994) . These data argue against the peripheral action of 
indomethacin to reverse the inhibition of gastric emptying- 
induced by i.v. IL-1/3. Indomethacin rather targets the central 
nervous system most likely to prevent IL-1/3 to stimulate CRF 
release from CNS sites. In vivo and in vitro experiments have 
shown that IL-1/3 activates hypothalamic CRF neurons in the PVN 
(Saphier et al., 1990; Ju et al., 1991; Watanabe et al., 1991;
Chover-Gonzalez et al. , 1993 ; Ericsson et al. , 1994; Ericsson et
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al., 1997), and endogenously released CRF in the brain is well 
established to inhibit gastric motor function in the rat (Taché 
et al. , 1993) . The present data and available neuroanatomical 
evidence are consistent with a possible involvement of PGs and 
CRF in brain mediated action of i.v. IL-l/3-induced delay of 
gastric emptying. Most likely CRF release is influenced by PGs, 
because it was shown that indomethacin did not influence i.c. 
CRF-induced delay of gastric emptying (Sütő et al., 1994b, 
Chapter 2.) . Recently a PG dependent activation of medullary 
ascending catecholaminerg neurons was shown by IL-lj3 (Ericsson 
et al., 1997), which may be responsible for the c-fos activation 
of CRF positive neurons in the PVN. Furthermore indomethacin did 
not influence basal gastric emptying, which shows that PGs are 
not the regulators of gastric emptying in normal rats. These 
findings support the notion that i.v. or i.c. IL-1/3 delays 
gastric emptying through the activation of PG and CRF dependent 
pathways within the CNS.
IL-ljS has a CNS site of action to release PGs, and CRF 
through the activation of type I receptors to inhibit gastric 
emptying. The release of CRF may be partially mediated by PGs 
after i.c. or fully after i.v. injection of IL-ljS.
6.2. LPS involves a peripheral release of IL-1 and CRF to delay 
gastric emptying.
LPS, the lipopolysaccharide component of the outer layer of 
gram negative bacteria (Galanos et al. , 1977) is a potent inducer 
of the immune system to defend against infection.
LPS injection into experimental animals produces local 
inflammation, and entering the circulation results in profound
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systemic effects such as fever (Saper et al., 1994), acute phase 
reaction (Kushner, 1982; van Gool et al., 1990), or in the most 
severe cases septic shock or disseminated intravascular 
coagulation (Cybulsky et al. , 1988). LPS influences different 
gastrointestinal functions: inhibits gastric acid secretion 
(Saperas et al., 1994), disrupts gastrointestinal mucosal 
integrity (Whittle et al. , 1987; Pique et al. , 1988) and 
gastrointestinal motility (Esplugues et al., 1989; Pons et al., 
1989) , alters colonic water and electrolyte transport (Ciancio 
et al., 1992). LPS was shown to act through the stimulation of 
the synthesis of ^further mediators, including IL-ljS and TNFce 
(Sirko et al., 1989; Zuckerman et al., 1989; Ulich et al., 1990; 
Foster et al. , 1993) . LPS was shown to induce hypothalamic 
(Hillhouse et al., 1993) and pituitary (Koenig et al., 1990) 
IL-ljS.
LPS and IL-ljS share many biological actions. LPS at low 
doses was demonstrated to activate CRF containing CNS pathways 
through IL-ljS to stimulate the hypothalamic-pituitary-adrenal 
axis (Elenkov et al., 1992a; Tilders et al., 1994). Peripheral 
injection of endotoxin, as it was shown by c-fos immunochemistry 
results in the activation of neurons within the CNS which are 
involved in the regulation of different autonomic, endocrine and 
behavioral responses during inflammation (Elmquist et al. , 1993 ; 
Wan et al. , 1993) . The injection of IL-ljS produces a similar 
expression of c-fos suggesting that the neuronal activation 
elicited by peripheral LPS injection may be mediated by IL-ljS 
(Rivest et al., 1992; Elmquist et al., 1993; Brady et al., 1994; 
Ericsson et al. , 1994; Ericsson et al. , 1997). IL-ljS is well 
known to modulate various gastric functions including the 
inhibition of gastric acid secretion (Uehara et al. , 1987; 
Saperas et al., 1990; Uehara et al., 1990) and motility (Robert
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et al. , 1991a; Robert et al., 1991b; McCarthy et al., 1992; van 
Miért et al. , 1992) . This action of IL-ljS is mediated by CNS 
release of CRF and PGs through the activation of type I IL-1 
receptors (Sütő et al. , 1994b; Sütő et al. , 1996, Chapters 
2., 3.) .
Interleukin receptor type I antagonist (Carter et al. , 1990; 
Eisenberg et al. , 1990; Hannum et al. , 1990; Arend, 1991; 
Dinarello et al. , 1991), a specific CRF receptor antagonist 
(Hernandez et al., 1993) and indomethacin were used to study the 
role of type I interleukin-1 receptors, CRF or PGs in the 
inhibition of gastric emptying by LPS. The present data show that 
peripheral administration of IL-lra antagonist prevented the 
gastroparesis elicited by i.p. administration of LPS. The central 
route of administration of IL-lra was ineffective. Increasing the 
dose of IL-lra a partial inhibition was observed which may rather 
be ascribed for the systemic appearance of IL-lra. Since IL-ra 
and IL-1/3 share a similar homology of amino acid sequence 
(Dinarello et al. , 1991) and IL-1/3 injected i.c. at the doses 
superior to 100 ng was found to leak to the periphery (Wallace 
et al. , 1992) , IL-lra at doses higher than 100 ng may be 
available for peripheral targets. The ineffectivity of i.c. IL-ra 
to inhibit LPS-induced gastroparesis may be due to several 
mechanisms: (1.) Neurons, other than CRF containing ones are 
activated by LPS or IL-ljS. Both IL-1/3 (i.v.) and LPS (i.p.) were 
shown to activate oxytocin and vasopressin (Mouri et al., 1993) 
immunoreactivity positive neurons within the CNS. Oxytocin is an 
inhibitory neuropeptide of gastric emptying within the central 
nervous system (Sütő et al. , 1994a) . (2.) In response to LPS, 
other mediators such as IL-6 or TNFa are produced (Cybulsky et 
al. , 198 8; Long et al. , 1990; Ulich et al. , 1990; Dunn, 19 92; 
Foster et al., 1993).
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It is well established that CRF injected both centrally and 
peripherally inhibits gastric emptying (Taché et al. , 1987; 
Sheldon et al., 1990; Barquist et al., 1992). CRF was originally 
isolated as the hypothalamic peptide which stimulates the 
secretion of corticotropin and j8 endorphin (Vale et al. , 1981), 
but it was also localized in different peripheral organs/tissues 
including peripheral T and B lymphocytes (Stephanou et al., 
1990), testes (Dufau et al. , 1993), trophoblastic and decidual 
tissue (Petraglia et al. , 1990), pancreas (Petrusz et al. , 1983), 
different types of cancers (Suda et al. , 1984a), the 
gastrointestinal tract (Kawahito et al., 1994; Kruseman et al., 
1982) or capsaicin sensitive primary afferent neurons (Skofitsch 
et al., 1984; Kamilaris et al., 1992). The peripheral source of 
CRF and the site of action is still obscure in the inhibition of 
gastric emptying by i.p. LPS.
The CRF receptor antagonist was injected i.c. or i.v. at the 
dose which established to prevent the 50% inhibition of gastric 
emptying induced by CRF or IL-l/S (Sütő et al. , 1994b; Sütő et 
al., 1994b, Chapters 2., 3.). However, the i.c. injection of CRF 
anatgonist was not able to influence LPS-induced gastroparesis, 
i.v. administration of CRF antagonist prevented LPS-induced delay 
of gastric emptying. CRF injected i.v. was demonstrated to delay 
gastric emptying of a noncaloric testmeal, but this finding shows 
that endogenous CRF released by LPS mediates gastroparesis 
induced by i.p. LPS injection.
Since LPS activates the afferent limb of the immune system 
mediated defense against infections or damage, it is likely that 
the activated PBMCs may release different mediators including CRF 
or IL-1 to interact and result in the net activation of the 
immune response. To support this hypothesis interactions between 
peripheral CRF and cytokines originating from PBMCs were found:
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(1 .) However it was not confirmed in further studies (Sobel, 
1990; Woudenberg et al. , 1992), IL-1 was shown to mediate the
effect of CRF and AVP on /3-endorphin production by human PBMC 
(Kavelaars et al. , 1989). (2.) CRF+AVP or IL-la/jS were shown to
stimulate the production of ACTH-like proteins in human 
mononuclear cells (Reder, 1992). (3.) A further study elucidated
that the presence of endotoxin determines the ability of PBMCs 
to synthesize IL-1 or TNF in response to CRF (Singh et al., 1990; 
Leu et al., 1992; Pereda et al., 1995).
These data do not allow to draw the final conclusion of the
target of IL-1 and CRF released upon LPS injection to delay*
gastric emptying of a noncaloric testmeal. Indomethacin was not 
able to influence the gastric emptying delayed by LPS. This 
finding also argues against the central IL-1/3 mediation, since 
it was sensitive to the blockade of PG synthesis (Sütő et al., 
1994b; Sütő et al., 1994b, Chapters 2., 3.). Furthermore the
central injection of the receptor antagonists did not influence 
the action of LPS. But the role of CNS can not be excluded, since 
subdiaphragmatic vagotomy blocks LPS induced hyperthermia 
(Watkins et al. , 1995), the transection of the hepatic branches 
of the vagus nerve inhibits illness-induced hyperalgesia (Watkins 
et al., 1994) and infusion of IL-1 into the portal vein results 
in increased firing of hepatic branches of the vagus nerve 
(Niijima, 1992) . The possible receptor sites for IL-1/3 are most 
likely localized in the hepatic branch of the vagus nerve. 
Macrophages located within the liver are the primary sites to 
detect foreign harmful compounds and respond with the release of 
cytokines and other inflammatory compounds which are able to 
stimulate directly or indirectly the sensory nerves of the vagus 
(Watkins et al. , 1994). This hypothesis needs further
investigations.
 .
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Based on these data LPS delays the gastric emptying of a 
noncaloric testmeal through the peripheral release of CRF and IL- 
1 which is not sensitive to blocking PG synthesis. The release 
of these mediators may a be part of the activation of the 
afferent limb of the immune system.
6.3. A non-neural source of calcitonin gene related peptide 
contributes to the inhibition of gastric emptying by 
intraperitoneal endotoxin in rats.
>
Capsaicin sensitive primary sensory afferents are involved 
in the postprandial regulation of the upper gastrointestinal 
tract (Holzer et al., 1994; Raybould et al., 1994; Zittel et al., 
1994) and in ileus due to surgery and/or peritoneal irritation 
(Holzer et al., 1986; Holzer et al., 1992; Plourde et al., 1993b; 
Takeuchi et al. , 1996) in rats. aCGP is abundantly localized
within the gastrointestinal tract stored mostly in primary 
sensory afferent fibres arising from the dorsal root ganglia, and 
a smaller amount was localized to in fibres originating from 
nodose ganglia (Sternini, 1992). A non neural source for CGRP was 
also described, since gastric mucosal lymphocytes produce CGRP 
mRNA as well (Jakab et al., 1993). CGRP injected intravenously 
potently inhibits gastric acid secretion, motility and the 
development of mucosal lesions (Maggi et al. , 1987; Taché et al. , 
1991; Taché, 1992a) . This effect of CGRP is mediated by its 
receptor type I and can be antagonized by the 8-37 fragment of 
human CGRP (hCGRP8_37) (Chiba et al. , 1989; Dennis et al. , 1990;
Donoso et al., 1990; Plourde et al., 1993a).
The CGRP type I receptor antagonist hCGRP8_37 increased the
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gastric emptying rate by 65% in the rats treated with the ED50 
dose of LPS. When LPS was injected at a submaximal dose hCGRP8_37 
did not influence the gastric emptying delayed by LPS. These data 
allows to draw the conclusion that endogenous CGRP released in 
response to LPS administration may at least partially mediate the 
gastroparesis induced by LPS. The Ed50 dose of LPS might represent 
a lower level of stimulation of the immune system, which may be 
influenced by hCGRP8„37. Higher doses of LPS may result in a robust 
production/release of mediators which can be hardly antagonized 
by the given dose of hCGRP8_37, however this dose was established 
previously of antagonize the submaximal inhibition of gastric 
emptying by CGRP (Plourde et al., 1993a). CGRP is not involved 
in the regulation of gastric emptying in intact rats since hCGRP8_ 
37 injected i.v. did not have any effect on gastric emptying.
Capsaicin pretreatment did not influence the gastric 
emptying of control animals. These data confirm the earlier 
findings which have shown that capsaicin sensitive primary 
sensory afferents are not involved in the regulation of gastric 
emptying during physiologic conditions (Coimbra et al. , 1996) . 
Capsaicin ablation of the capsaicin sensitive primary sensory 
afferents did not influence the inhibition of gastric emptying 
after LPS treatment, and hCGRP8_37 still had a partial inhibition 
on LPS-delayed gastric emptying. Recently gastric mucosal 
lymphocytes were shown to express CGRP mRNA (Jakab et al. , 1993) . 
Whether these cells contribute to the increase of plasma CGRP 
levels following LPS treatment of experimental animals (Wang et 
al., 1991; Griffin et al., 1992; Wang et al., 1992a; Wang et al., 
1992b; Hüttemeier et al., 1993) is not proven yet, but allows to 
consider peripheral lymphocytes as an alternative capsaicin 
insensitive source of CGRP. The inhibition of gastric emptying
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was observed 1 h after (Chapter 4.) the injection of the present 
dose of LPS. This delay of LPS mediated gastroparesis may be 
ascribed to an inducible mediator, which results in the release 
of CGRP. The most likely candidate is IL-1 to release CGRP, since 
LPS act through IL-1 and TNF (Cybulsky et al., 1988; Long et al., 
1990; Ulich et al., 1990; Dunn, 1992) and IL-1 was shown to act 
partially through CGRP (Coimbra et al. , 1996). This hypothesis 
is strengthened by the ability of IL-1 receptor antagonist 
injected i.p. to fully inhibit the gastroparesis induced by the 
same dose of LPS (Chapter 3.) . IL-l/S was shown to sensitize 
capsaicin sensitive primary afferents through local release of 
prostaglandins (Leung et al. , 1987) and nitric oxide (Sternini, 
1992), but alone was unable to release any mediator form these 
nerve endings.
An another explanation for hCGRP8.37 to inhibit the LPS- 
induced delay of gastric emptying is a possible interaction with 
adrenomedullin (Vine et al. , 1996) . This peptide was recently 
isolated from phaemochromocytoma tissue, has a potent ability to 
delay gastric emptying (Martinez et al. , 1997) , and shares common 
receptors with CGRP (Vine et al., 1996). This hypothesis needs 
further confirmation utilizing specific adrenomedullin receptors.
LPS challenge of the immune system results in the delay of 
gastric emptying which is mediated by CGRP acting on type I 
receptors. CGRP is released most likely from a non neural source.
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6.4. New results.
(1.) Both central and peripheral injection of IL-1/3 induced 
potent inhibition of gastric emptying. The central dose of IL-ljS 
was 33 fold lower than the peripheral dose, which supports a 
central target for IL-1/3 to delay the gastric emptying of a 
noncaloric testmeal.
(2.) IL-1/3 delays gastric emptying through the activation of
specific interleukin-1 receptors. These receptors are type 1 
Tcell/fibroblast receptors for IL-1.
(3.) IL-ljS is not > involved in the regulation of basal gastric 
emptying.
(4.) The gastroparesis elicited by both central and peripheral 
IL-ljS is regulated by CNS prostaglandins.
(5.) Central IL-ljS involves CRF release to delay gastric 
emptying.
(6.) Peripheral IL-ljS is partially mediated by central release 
of CRF.
(7.) LPS injected intraperitoneally dose dependently decreased 
gastric emptying.
(8.) The gastroparesis induced by LPS has a delayed onset of 
action and is long lasting, most likely due to the synthesis 
and/or release of secondary mediator molecules such as IL-ljS or 
CRF.
(9.) This is the first time to demonstrate that LPS delayed 
gastric emptying is mediated by endogenously released peripheral 
IL-jS and CRF.
(10.) LPS-induced delay of gastric emptying is not prostaglandin 
dependent.
(11.) LPS-induced delay of gastric emptying is partially mediated
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by CGRP, originated from a nonneural, capsaicin resistant source.
These data further support interactions between the immune system 
and neuroregulation of gastric function which may have 
implications in the understanding of gastric stasis associated 
with some pathology activating the immune system
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